[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 202
1. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol; 2010 Jun;19(2):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
  • As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin.
  • Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated.
  • Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P).
  • In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated.
  • In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively.
  • A statistically significant correlation between hMAM and malignancy was found in the entire population (DOR=14.68, P<0.001) and in the male (DOR=15.00, P<0.001) or female (DOR=12.77, P<0.001) groups. hMAM RT-PCR increased the diagnostic rate of malignant PEs as it allowed us to detect as malignant 32.1% of cytologically negative PEs.
  • In female patients the positivity of hMAM indicated with higher probability (50.8%) the origin of PEs from breast cancer but lower probability from LC (17%), MM (9.4%), or other cancers (15.1%), whereas in male patients it indicated with similar probability (about 40%) the origin from LC or MM.
  • Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Neoplasm Proteins / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Male. Mammaglobin A. Middle Aged. United States. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502186.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


2. Breiting L, Christensen L, Dahlstrøm K, Breiting V, Winther JF: Primary mucinous carcinoma of the skin: a population-based study. Int J Dermatol; 2008 Mar;47(3):242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary mucinous carcinoma of the skin (PMCS) is a rare malignant tumor deriving from the sweat glands.
  • It is typically located on the head and is often mistaken for a metastasis from a more common primary tumor of the breast or gastrointestinal tract.
  • CONCLUSION: PMCS is a rare, slow-growing tumor which rarely metastasizes and is associated with low mortality.
  • However, the precise number may be higher, since PMCS is an indolent tumor, which may be mistaken for a benign tumor and thus not always examined histologically.
  • [MeSH-minor] Aged. Aged, 80 and over. Denmark / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Registries. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289323.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Smarrito S, Salmon R: [Desmoid tumor in a male breast in the context of Gardner's syndrome. Case report]. Ann Chir; 2005 Jan;130(1):40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoid tumor in a male breast in the context of Gardner's syndrome. Case report].
  • [Transliterated title] Tumeur desmoïde du sein chez l'homme dans le cadre d'un syndrome de Gardner. A propos d'un cas.
  • Fibromatosis (Desmoid tumor) of the male breast is an exceptional location.
  • We present a case of such a tumor, in the context of Gardner's syndrome.
  • A palpable mass was discovered in the right breast of a 52 years old man, with a history of rectocolic adenomatous polyposis.
  • Mammography ant thoracic CT scan showed a stellar tumor, mimicking a breast cancer.
  • Treatment consisted of wide excision and histology revealed a desmoid tumor.
  • Desmoid tumors of the breast are benign lesions; they should be widely excised because of a high risk of recurrence.
  • Coloscopy is indicated in the presence of mammary fibromatosis, to look for associated multiple polyps, confirming the diagnosis of Gardner's syndrome.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / surgery. Fibromatosis, Aggressive / pathology. Fibromatosis, Aggressive / surgery. Gardner Syndrome / complications
  • [MeSH-minor] Colonoscopy. Humans. Male. Middle Aged. Risk Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15664376.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM: Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ; 2010 Sep;17(9):1511-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We here showed for the first time, in contrast to the reported promoting action of GPR30 on the growth of breast and ovarian cancer cells, that activation of GPR30 by the receptor-specific, non-estrogenic ligand G-1 inhibited the growth of androgen-dependent and androgen-independent prostate cancer (PCa) cells in vitro and PC-3 xenografts in vivo.
  • However, G-1 elicited no growth or histological changes in the prostates of intact mice and did not inhibit growth in quiescent BPH-1, an immortalized benign prostatic epithelial cell line.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biotechniques. 2004 May;36(5):826-8, 830, 832-3 [15152603.001]
  • [Cites] EMBO J. 2009 Mar 4;28(5):523-32 [19153601.001]
  • [Cites] J Urol. 1984 Sep;132(3):474-9 [6206240.001]
  • [Cites] Endocr Rev. 1987 Aug;8(3):338-62 [3308446.001]
  • [Cites] Cell. 1988 Dec 2;55(5):875-85 [3142689.001]
  • [Cites] Nature. 1991 Oct 17;353(6345):670-4 [1922387.001]
  • [Cites] Nature. 1991 Dec 12;354(6353):494-6 [1749429.001]
  • [Cites] Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57 [1751545.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):915-27 [1545823.001]
  • [Cites] EMBO J. 1993 Feb;12(2):479-87 [8382609.001]
  • [Cites] J Cell Biol. 1993 Sep;122(5):1089-101 [8394846.001]
  • [Cites] Adv Second Messenger Phosphoprotein Res. 1993;28:237-44 [8398409.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1190-3 [8118804.001]
  • [Cites] EMBO J. 1994 Nov 15;13(22):5421-32 [7957108.001]
  • [Cites] Cell. 1995 Jan 27;80(2):179-85 [7834738.001]
  • [Cites] EMBO J. 1995 Sep 15;14(18):4514-22 [7556094.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):448-52 [9012803.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):546-57 [9418901.001]
  • [Cites] Trends Biochem Sci. 1998 May;23(5):174-8 [9612081.001]
  • [Cites] Nutr Cancer. 1998;32(3):123-31 [10050261.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):29572-81 [10506225.001]
  • [Cites] J Biol Chem. 1999 Oct 15;274(42):29677-82 [10514438.001]
  • [Cites] Endocrinology. 2005 Feb;146(2):624-32 [15539556.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4632-8 [15557324.001]
  • [Cites] Science. 2005 Mar 11;307(5715):1625-30 [15705806.001]
  • [Cites] Trends Endocrinol Metab. 2005 Oct;16(8):362-7 [16125968.001]
  • [Cites] Mol Endocrinol. 2006 Mar;20(3):631-46 [16239258.001]
  • [Cites] Nat Chem Biol. 2006 Apr;2(4):207-12 [16520733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9063-8 [16754886.001]
  • [Cites] Cell Prolif. 2006 Aug;39(4):261-79 [16872362.001]
  • [Cites] Mol Endocrinol. 2006 Sep;20(9):1996-2009 [16645038.001]
  • [Cites] Mol Pharmacol. 2006 Oct;70(4):1414-23 [16835357.001]
  • [Cites] Endocrinology. 2006 Dec;147(12):5557-63 [16946015.001]
  • [Cites] Nucleic Acids Res. 2006;34(21):6272-85 [17098936.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1859-66 [17308128.001]
  • [Cites] Life Sci. 2007 Oct 13;81(17-18):1323-31 [17936851.001]
  • [Cites] Endocr Rev. 2007 Dec;28(7):726-41 [17916740.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):350-3 [18406603.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e19 [18590585.001]
  • [Cites] Endocrinology. 2008 Aug;149(8):4024-34 [18467434.001]
  • [Cites] Mol Endocrinol. 2008 Sep;22(9):2116-27 [18617595.001]
  • [Cites] Endocrinology. 2008 Oct;149(10):4846-56 [18566127.001]
  • [Cites] Circ Res. 2009 Feb 13;104(3):288-91 [19179659.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3175-82 [10866308.001]
  • [Cites] Mol Endocrinol. 2000 Oct;14(10):1649-60 [11043579.001]
  • [Cites] J Biol Chem. 2001 Feb 23;276(8):5570-6 [11096075.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):4010-7 [11726647.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12710-7 [11821415.001]
  • [Cites] Mol Endocrinol. 2002 May;16(5):938-46 [11981029.001]
  • [Cites] J Cell Physiol. 2002 Aug;192(2):151-9 [12115721.001]
  • [Cites] Endocrinology. 2002 Dec;143(12):4620-6 [12446589.001]
  • [Cites] J Biol Chem. 2002 Dec 27;277(52):50550-6 [12414794.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36966-72 [12857729.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27008-16 [15090535.001]
  • (PMID = 20203690.001).
  • [ISSN] 1476-5403
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006096-17; United States / NCI NIH HHS / CA / CA112532; United States / NIEHS NIH HHS / ES / R01 ES015584; United States / NIEHS NIH HHS / ES / ES015584; United States / NCI NIH HHS / CA / R01 CA112532; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NCI NIH HHS / CA / R01 CA015776; United States / NCI NIH HHS / CA / CA015776; United States / NCI NIH HHS / CA / R01 CA112532-04; United States / NCI NIH HHS / CA / R01 CA015776-29; United States / NIEHS NIH HHS / ES / R01 ES015584-02; United States / NIEHS NIH HHS / ES / ES015584-02; United States / NIEHS NIH HHS / ES / ES006096-17; United States / NIEHS NIH HHS / ES / ES006096
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone; 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Antineoplastic Agents; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclopentanes; 0 / Flavonoids; 0 / GPER protein, human; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-fos; 0 / Proto-Oncogene Proteins c-jun; 0 / Quinolines; 0 / RNA, Small Interfering; 0 / Receptors, Estrogen; 0 / Receptors, G-Protein-Coupled; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / MAPK1 protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ NIHMS170211; NLM/ PMC2897932
  •  go-up   go-down


5. Lan Y, Zhang Y, Wang J, Lin C, Ittmann MM, Wang F: Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer; 2008 Aug 1;123(3):543-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forced expression of Cks1 and Cks2 in benign prostate tumor epithelial cells promoted cell population growth.
  • Knockdown of Cks1 expression in malignant prostate tumor cells inhibited proliferation, anchorage-independent growth, and migration activities, whereas knockdown of Cks2 expression induced programmed cell death and inhibited the tumorigenicity.
  • Collectively, the data suggest that elevated expression of Cks1 contributes to the tumorigenicity of prostate tumor cells by promoting cell growth and elevated expression of Cks2 protects the cells from apoptosis.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 2005 Feb;41(2):105-16 [15695111.001]
  • [Cites] Mol Gen Genet. 1986 Feb;202(2):291-3 [3010051.001]
  • [Cites] Mol Cell Biol. 1989 May;9(5):2034-41 [2664468.001]
  • [Cites] Genes Dev. 1990 Aug;4(8):1332-44 [2227411.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5369-78 [9393762.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1998;59:135-76 [9427842.001]
  • [Cites] Int J Cancer. 1999 Jul 2;82(1):98-104 [10360827.001]
  • [Cites] Am J Pathol. 2004 Dec;165(6):2147-55 [15579456.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55348-54 [15513912.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):51-63 [15652749.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):310-6 [16116475.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2461-9 [16353136.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):599-607 [16572426.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1511-24 [16705040.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):521-31 [16865252.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):668-75 [16826582.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9986-94 [17047061.001]
  • [Cites] J Urol. 2006 Nov;176(5):2285-9 [17070313.001]
  • [Cites] Int J Oncol. 2006 Dec;29(6):1337-47 [17088971.001]
  • [Cites] J Biol Chem. 2007 Jan 5;282(1):390-6 [17092932.001]
  • [Cites] Development. 2007 Feb;134(4):723-34 [17215304.001]
  • [Cites] FEBS Lett. 2007 Mar 20;581(6):1166-72 [17336302.001]
  • [Cites] Mod Pathol. 2007 Apr;20(4):497-507 [17384652.001]
  • [Cites] Breast Cancer Res. 2007;9(2):R25 [17428314.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1336-46 [15717322.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23716-24 [17569667.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2249-61 [15900300.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4672-87 [15940270.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5246-51 [15897880.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R737-44 [16168119.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):17-26 [16341208.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):148-68 [11237531.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):321-4 [11231585.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):639-50 [11463388.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):41-7 [12507555.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Cell Cycle. 2003 Jan-Feb;2(1):59-63 [12695690.001]
  • [Cites] Science. 2003 Apr 25;300(5619):647-50 [12714746.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4936-44 [12941818.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8784-90 [14695195.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):921-30 [14737122.001]
  • [Cites] Lab Invest. 2004 May;84(5):588-96 [15064772.001]
  • [Cites] Genes Dev. 2004 Apr 15;18(8):862-76 [15078817.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3507-14 [3322810.001]
  • (PMID = 18498131.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA096824-01A1; United States / NCI NIH HHS / CA / R01 CA096824-01A1; United States / NCI NIH HHS / CA / CA096824-05; United States / NCI NIH HHS / CA / R01 CA096824-05; United States / NCI NIH HHS / CA / R56 CA096824; United States / NCI NIH HHS / CA / CA096824; United States / NCI NIH HHS / CA / R01 CA096824
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKS1B protein, human; 0 / CKS2 protein, human; 0 / Carrier Proteins; 0 / Cell Cycle Proteins; 0 / DNA, Complementary; 0 / RNA, Messenger; EC 2.7.- / Protein Kinases; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / CDC28 Protein Kinase, S cerevisiae; EC 2.7.11.22 / Cks1 protein, mouse; EC 2.7.11.22 / Cks2 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinases
  • [Other-IDs] NLM/ NIHMS93124; NLM/ PMC3262990
  •  go-up   go-down


6. Nassar A, Amin MB, Sexton DG, Cohen C: Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol; 2005 Sep;13(3):252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, AMACR has been demonstrated to be overexpressed in localized and metastatic prostate cancer and in high-grade prostatic intraepithelial neoplasia but not in normal prostatic glands, suggesting that it may be an important tumor marker.
  • This study examines AMACR expression in a variety of human cancers to assess its viability as a tumor marker in the clinical setting.
  • Cancers studied included breast (94 cases), prostate (38), lung (28), endometrium (27), colon (29), ovary (26), and melanoma (21).
  • A section of prostate cancer and prostatic intraepithelial neoplasia was used as positive control.
  • AMACR protein overexpression was found in several cancers, including prostate (34/38 [89.5%]), colon (13/29 [44.8%]), lung (4/28 [14.3%]), melanoma (2/21 [9.5%]), endometrium (2/27 [7.4%]), and breast (3/94 [3.2%]).
  • AMACR expression was not present in any of the normal tissues nor in benign prostatic tissue associated with prostate carcinomas.
  • This study suggests that AMACR is potentially an important tumor marker, particularly for prostate and colon cancer.
  • It may be a useful adjunct to an immunohistochemical panel employed in the differential diagnosis of colon versus ovarian and breast carcinoma; the latter two infrequently express AMACR.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082251.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


7. Ewan King L, Li X, Cheikh Saad Bouh K, Pedneault M, Chu CW: Human kallikrein 10 ELISA development and validation in breast cancer sera. Clin Biochem; 2007 Sep;40(13-14):1057-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 10 ELISA development and validation in breast cancer sera.
  • There is significant interest in measuring hK10 which may act as a tumor suppressor in some cancers.
  • We have developed an ELISA for hK10 and determined its analytical and clinical performance in normal and breast cancer sera.
  • The assay was analytically validated and used to determine serum levels of hK10 in a set of breast cancer, benign breast disease and normal samples.
  • Concentrations were not age related and were not significantly different from benign fibrocystic disease or breast cancer.
  • However, in a subset of breast cancer patients with both early and late stage disease, serum hK10 levels were elevated, at >1.55 ng/mL, above all normal female and benign disease samples.
  • CONCLUSIONS: We report in detail the analytical performance of a colorimetric hK10 ELISA validated in human serum and report for the first time the hK10 serum concentration in benign and breast cancer samples.
  • [MeSH-major] Breast Neoplasms / blood. Enzyme-Linked Immunosorbent Assay / methods. Kallikreins / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585892.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.- / KLK10 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


8. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R: Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest; 2006 Dec;24(8):727-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningioma is a benign central nervous system tumor that is often progesterone-but not estrogen-receptor positive, making long-term antiprogestational therapy a logical treatment strategy.
  • Serial follow-up allowed evaluation for tolerability and side effects of long-term therapy as well as observation for efficacy (tumor shrinkage or improvement in visual fields).
  • Repeated oral administration was well tolerated with mild fatigue (22 patients), hot flashes (13 patients), and gynecomastia/breast tenderness (6 patients) being the most common side effects.
  • Minor responses (improved automated visual field examination or improved CT or MRI scan) were noted in 8 patients, 7 of whom were male or premenopausal female.
  • Minor regression of meningioma that can result in significant clinical benefit is suggested in the male and premenopausal female subgroups of patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162554.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2P30 CA14089
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Synthetic; 320T6RNW1F / Mifepristone
  •  go-up   go-down


9. Kim JE, Kim HJ, Choi JM, Lee KH, Kim TY, Cho BK, Jung JY, Chung KY, Cho D, Park HJ: The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br J Dermatol; 2010 Nov;163(5):959-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent evidence suggests cathelicidin LL-37 to be a growth factor for various human cancers such as lung cancer, ovarian cancer and breast cancer.
  • Immunohistochemical analysis of melanoma, nonmelanoma skin cancer and precancerous and benign skin lesions was performed.
  • [MeSH-major] Antimicrobial Cationic Peptides / metabolism. Melanoma / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor / metabolism. Cell Movement / physiology. Cell Proliferation. Enzyme-Linked Immunosorbent Assay. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Precancerous Conditions / metabolism. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 20977442.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 143108-26-3 / CAP18 lipopolysaccharide-binding protein
  •  go-up   go-down


10. Salemi M, Calogero AE, Vicari E, Migliore E, Zaccarello G, Cosentino A, Amore M, Tricoli D, Castiglione R, Bosco P, Rappazzo G: A high percentage of skin melanoma cells expresses SPANX proteins. Am J Dermatopathol; 2009 Apr;31(2):182-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of SPANX (sperm protein associated with the nucleus in the X chromosome) gene family has been reported in many tumors, such as melanoma, myeloma, glioblastoma, breast carcinoma, ovarian cancer, testicular germ cell tumors, and hematological malignancies.
  • The expression of SPANX proteins was evaluated by immunohistochemistry in normal skin (n = 12), melanomas (n = 21), and benign nevi (n = 10), using a polyclonal antibody raised in our laboratory.
  • Benign nevi had an intermediate number of cells expressing SPANX proteins (25% +/- 8.5%), which resulted significantly higher than normal skin cells and significantly lower than skin melanoma cells.
  • In melanoma cells, the labeling was mostly nuclear, sometimes incomplete or limited to the perinuclear wall, even if cytoplasmic staining was also seen in SPANX-positive tumor cells.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibodies. Antibody Specificity. Biopsy. Epitopes / immunology. Epitopes / metabolism. Female. Humans. Immunohistochemistry. Male. Mice. Middle Aged. Multigene Family / physiology. Neoplasms / metabolism. Neoplasms / pathology. Nevus / metabolism. Nevus / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318807.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Epitopes; 0 / Nuclear Proteins; 0 / SPANXA1 protein, human
  •  go-up   go-down


11. Li BJ, Wang JY, Wang HY, Huang XP, Zhang LJ, Long H, Yang MT, Rong TH: [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient]. Zhonghua Zhong Liu Za Zhi; 2006 Oct;28(10):766-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient].
  • OBJECTIVE: To investigate the expression of the human mammoglobin (hMAM) mRNA in bone marrow and its clinical significance in the breast cancer patient.
  • METHODS: Expression of hMAM mRNA was detected using nested reverse transcription polymerase chain reaction (RT-PCR) in the bone marrow aspiration sample from 75 breast cancer patients, 15 patients with benign breast lesions and 8 healthy volunteers as control.
  • The hMAM mRNA was found to be positively expressed by RT-PCR in 21 of 75 breast cancer patients with a positive rate of 28.0%.
  • However, hMAM mRNA expression was not detected in the bone marrow aspiration samples from patients with benign breast lesions and healthy volunteers.
  • The hMAM mRNA expression was positively correlated with axillary nodal involvement and progesterone receptor (PR) status (P < 0.05) as well as Ki67 expression in breast cancer tissue (chi2 = 4.936, P = 0.026), but not with age, tumor size, clinical stage, or estrogen receptor (ER) status (P > 0.05).
  • CONCLUSION: RT-PCR is quite sensitive and has a high specificity in detecting the presence of hMAM mRNA in the bone marrow from breast cancer patients.
  • Thereupon, hMAM mRNA may be useful as a molecular biomarker in detecting disseminated tumor cells (DTC) in the bone marrow of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / genetics. Breast Neoplasms, Male / genetics. Neoplasm Proteins / genetics. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Female. Fibroadenoma / genetics. Fibroadenoma / pathology. Humans. Ki-67 Antigen / genetics. Lymphatic Metastasis. Male. Mammaglobin A. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Progesterone / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366790.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


12. Yang DM, Kim HC, Lim JW, Jin W, Ryu CW, Kim GY, Cho H: Sonographic findings of groin masses. J Ultrasound Med; 2007 May;26(5):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common benign tumor of the inguinal region was a lipoma.
  • Other benign tumors of the groin included leiomyomas, dermoid cysts, epidermoid cysts, and lymphangiomas.
  • Secondary malignant tumors of the inguinal regions were metastatic lymphomas and metastatic carcinomas of the lung, breast, ovary, and gastrointestinal tract.
  • CONCLUSIONS: Although there was substantial overlap of sonographic findings in the various inguinal masses, clinical history and certain sonographic details can assist in making the correct diagnosis.
  • [MeSH-minor] Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460003.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kammori M, Izumiyama N, Nakamura K, Kurabayashi R, Kashio M, Aida J, Poon SS, Kaminishi M: Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization. Oncology; 2006;71(5-6):430-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization.
  • In conclusion, our TCR method can be used to distinguish between benign and malignant tissue in esophageal lesions.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Esophageal Neoplasms / diagnosis. Esophagus / pathology. In Situ Hybridization, Fluorescence / methods. Telomere / genetics
  • [MeSH-minor] Aged. Anaphase / genetics. Biomarkers, Tumor / biosynthesis. Centromere / pathology. Chromosomal Instability / genetics. Humans. Male. Middle Aged. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17878747.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Guo Z, Wang Z, Li J, Li XD: [Reconstruction with a new type of combined reconstruction following excision of periacetabular tumors]. Zhonghua Wai Ke Za Zhi; 2008 Jun 15;46(12):895-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the reconstructive effect of a new pattern of combined reconstruction after periacetabular tumor resections.
  • METHODS: Between March 2001 and March 2007, tumor resections and new pattern of combined reconstructions which consisted of screw-rod system, acetabular reinforcement shell, antibiotic cement and total hip arthroplasty techniques were performed in 23 patients with periacetabular tumors.
  • Three metastatic bone tumors were also included in this study, and the original sites were thyroid, breast, and ovary.
  • Three primary benign bone tumors belonged to stage III.
  • CONCLUSIONS: This new combined reconstruction is an effective way to rebuild pelvic ring and maintain hip function with low complication rate after periacetabular tumor resections.
  • [MeSH-minor] Adolescent. Adult. Aged. Arthroplasty, Replacement, Hip. Bone Screws. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035146.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Di Carlo A, Terracciano D, Mariano A, Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol; 2005 May;26(5):1363-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, several MMPs were implicated in creating an environment that supports the initiation and maintenance of tumor growth.
  • Of these patients, 22 had malignant pleural effusion, consisting of 11 breast carcinomas and 11 lung carcinomas (7 squamous cell carcinomas and 4 adenocarcinomas), and 8 patients had benign effusions.
  • The MMP-9/MMP-2 ratio was enhanced in cancer patients compared with benign diseases and healthy individuals.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Pleural Effusion / enzymology. Pleural Effusion / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809729.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


16. Shams TM, Samaka RM, Shams ME: Maspin protein expression: a special feature of papillary thyroid carcinoma. J Egypt Natl Canc Inst; 2006 Sep;18(3):274-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Mammary serine protease inhibitor (Maspin) is down regulated in breast and prostate cancers and is considered as a tumor suppressor gene.
  • On the contrary, it is over expressed in pancreatic and ovarian carcinomas and is reported to be an oncogene rather than a tumor suppressor gene.
  • The studies of maspin expression in thyroid neoplasia, the focus of this study, are limited.
  • We, therefore, carried out this work in order to detect the frequency and pattern of maspin expression in thyroid neoplasia.
  • MATERIAL & METHODS: An immunohistochemical approach was performed on 63 thyroid specimens showing different benign and malignant thyroid lesions.
  • There was no statistically significant relation between maspin positive cases and the studied clinicopathological parameters including patient's age, sex and tumor stage.
  • On the other hand, it was statistically significant as regards tumor multicentricity, vascular and lymphatic invasion, as well as lymph node metastasis.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Serpins / analysis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Thyroid Gland / chemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671538.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


17. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
  • L1 was absent in breast carcinoma, gastrointestinal tract carcinomas, gastrointestinal carcinoids, renal clear-cell carcinomas, prostate adenocarcinomas, and mesotheliomas.
  • Surprisingly, L1 expression in established breast and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


18. Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D: Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat; 2007 Oct;105(2):169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.
  • BACKGROUND: Male breast cancer (MBC) commonly expresses hormone receptors and there is anecdotal evidence of disease responsivity to aromatase inhibitors in the metastatic setting.
  • Specimens were reviewed for standard pathologic characteristics and tumor blocks were incorporated into three TMA's (four 1 mm cores per tumor).
  • ITA staining intensity was compared to control, benign hepatic tissue and if greater than or equal to liver was scored positive and if less than liver was scored negative.
  • Median tumor size was 2.6 cm (0.3-8.0 cm) and 22(41%) had nodal metastases.
  • [MeSH-major] Aromatase / metabolism. Breast Neoplasms, Male / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Humans. Immunoenzyme Techniques. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies. Survival Rate. Tissue Array Analysis


19. Chen L, Madura K: Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res; 2005 Jul 1;65(13):5599-606
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
  • The activation of this pathway in various cancers and malignancies has been described, and several genetic determinants of breast cancer, including BRCA1 and BRCA2, are linked to protein degradation.
  • To investigate the involvement of the Ub/proteasome system in breast cancer, we examined a collection of 25 patient-matched breast cancer and normal adjacent tissues and detected activation of numerous components of the Ub/proteasome pathway.
  • The activity of the proteasome, and levels of proteasome subunits and various targeting factors, were increased in >90% of primary breast cancer tissue specimens.
  • In contrast, no activation was observed in benign solid tumors, indicating that the response is specific to abnormal growth in neoplastic cells.
  • Additionally, the accumulation of high levels of certain Ub-conjugating enzymes (UbcH1, UbcH2, and UbcH5), was specific to breast cancer, as no change in abundance was detected in primary colon cancer tissue extracts.
  • Surprisingly, the Ub/proteasome system was not activated in a well-characterized cell culture-based breast cancer model system.
  • Collectively, these findings suggest that the analysis of primary breast cancer tissue samples will be indispensable for the biochemical characterization of neoplastic growth and for the development of therapeutics.
  • [MeSH-major] Breast Neoplasms / enzymology. Peptide Elongation Factor 1 / metabolism. Proteasome Endopeptidase Complex / metabolism. Ubiquitin-Conjugating Enzymes / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Tumor Cells, Cultured. Ubiquitin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994932.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83875
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Elongation Factor 1; 0 / Ubiquitin; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  •  go-up   go-down


20. Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, Erickson D, Raffeld M, Filie AC, Abati A: Diagnostic effects of prolonged storage on fresh effusion samples. Diagn Cytopathol; 2007 Jan;35(1):6-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specimens evaluated included four pleural (3 benign, 1 breast adenocarcinoma) and six peritoneal (2 ovarian adenocarcinomas, 1 malignant melanoma, 2 mesotheliomas, 1 atypical mesothelial) effusions.
  • [MeSH-major] Artifacts. Ascitic Fluid / pathology. Cytodiagnosis / methods. Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. Specimen Handling / methods
  • [MeSH-minor] Adult. Biomarkers, Tumor. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Time Factors

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173298.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


21. Drees R, Hünigen H, Wagner S, Schnorr J, Plendl J, Taupitz M: Peripheral washout phenomenon in an animal tumour model: comparison of dynamic magnetic resonance imaging using a small molecular contrast medium with histology. Vet Comp Oncol; 2008 Sep;6(3):151-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The peripheral washout sign was first described in delayed dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using a small molecular contrast medium in solid lesions of the human breast and liver.
  • It was found to be 100% specific for malignant lesions and could therefore potentially be used as an additional noninvasive diagnostic tool differentiating malignant from benign lesions.
  • [MeSH-minor] Animals. Cell Line, Tumor. Male. Rats. Rats, Inbred Strains. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178675.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


22. Ismail MF, Aly MS, Khaled HM, Mohamed HM: Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer. Ger Med Sci; 2009;7:Doc03
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
  • Breast cancer is a leading cause of cancer-related deaths in women worldwide.
  • Amplification of the two oncogenes HER-2/neu and c-myc and inactivation of the tumor suppressor gene p53 are frequently encountered in breast carcinomas.
  • The study was conducted on 34 tissue samples obtained from 33 females and 1 male with breast carcinomas and 17 samples obtained from 16 females and 1 male with benign breast lesions.
  • Results revealed that the level of HER-2/neu, c-myc and p53 in the malignant group was significantly increased as compared to the benign group.
  • The sensitivity of the investigated markers significantly increased with larger tumor size.
  • Concerning tumor grade, HER-2/neu and p53 showed a significant increase in low-grade tumors whereas c-myc showed a highly significant increase in high-grade tumors.
  • [MeSH-major] Breast Neoplasms / genetics. In Situ Hybridization, Fluorescence / methods. Proto-Oncogene Proteins c-myc / analysis. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biopsy. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / genetics. Egypt / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Nucleic Acid Amplification Techniques / methods. Prevalence. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Jan;156(1):183-91 [10623666.001]
  • [Cites] Diagn Mol Pathol. 2007 Dec;16(4):207-10 [18043283.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):211-21 [10832591.001]
  • [Cites] Indian J Exp Biol. 2000 Mar;38(3):225-30 [10927863.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):647-63 [10942052.001]
  • [Cites] Acta Oncol. 2000;39(3):327-33 [10987229.001]
  • [Cites] Endocr Relat Cancer. 2000 Sep;7(3):143-64 [11021963.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6093-101 [11156522.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6102-14 [11156523.001]
  • [Cites] Int J Cancer. 2001 Jul 20;95(4):266-70 [11400121.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):337-44 [11553865.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1481-8 [11888924.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jul;74(1):25-31 [12150449.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):690-4 [12548612.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1612-9 [15083194.001]
  • [Cites] J Pathol. 2004 Aug;203(4):918-26 [15258994.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):246-55 [15323142.001]
  • [Cites] Nature. 1986 Feb 27-Mar 5;319(6056):783-4 [3005871.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5 [1351679.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Cell Growth Differ. 1993 Jan;4(1):41-7 [8424905.001]
  • [Cites] Curr Opin Genet Dev. 1995 Feb;5(1):97-104 [7749333.001]
  • [Cites] J Pathol. 1995 Nov;177(3):225-32 [8551383.001]
  • [Cites] Oncogene. 1996 Jul 4;13(1):63-72 [8700555.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):323-9 [9563780.001]
  • [Cites] Breast Cancer Res Treat. 1998 May;49(1):35-9 [9694609.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):100-8 [9739012.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Am J Clin Pathol. 1999 Oct;112(4):459-69 [10510669.001]
  • [Cites] Cancer. 2005 Mar 1;103(5):900-5 [15643600.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1909-17 [15753390.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):633-41 [15756435.001]
  • [Cites] Histopathology. 2005 Apr;46(4):431-41 [15810955.001]
  • [Cites] Rev Med Chir Soc Med Nat Iasi. 2004 Jul-Sep;108(3):657-61 [15832994.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):634-9 [16021569.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jul;47(3):340-2 [16295419.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):433-9 [16297088.001]
  • [Cites] Clin Exp Metastasis. 2005;22(6):495-502 [16320112.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1058-79 [16457687.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):424-8 [16497871.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5330-7 [16707459.001]
  • [Cites] Oncologist. 2006 Sep;11(8):857-67 [16951389.001]
  • [Cites] Int J Oncol. 2006 Oct;29(4):973-80 [16964393.001]
  • [Cites] Int J Biol Markers. 2006 Jul-Sep;21(3):131-40 [17013794.001]
  • [Cites] Hua Xi Yi Ke Da Xue Xue Bao. 1998 Dec;29(4):399-401 [10743237.001]
  • (PMID = 19675743.001).
  • [ISSN] 1612-3174
  • [Journal-full-title] German medical science : GMS e-journal
  • [ISO-abbreviation] Ger Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2716551
  • [Keywords] NOTNLM ; HER-2/neu / breast cancer / c-myc / fluorescent in situ hybridization (FISH) / genetic alterations / p53
  •  go-up   go-down


23. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M: Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res; 2006 Jul 1;12(13):3942-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The integrin alpha(v)beta3 plays a key role in angiogenesis and tumor cell metastasis and is therefore an important target for new therapeutic and diagnostic strategies.
  • EXPERIMENTAL DESIGN: Nineteen patients with solid tumors (musculoskeletal system, n = 10; melanoma, n = 4; head and neck cancer, n = 2; glioblastoma, n = 2; and breast cancer, n = 1) were examined with PET using [18F]Galacto-RGD before surgical removal of the tumor lesions.
  • Intensity of staining (graded on a four-point scale) and the microvessel density of alpha(v)beta3-positive vessels were determined and correlated with SUV and tumor/blood ratios (T/B).
  • All other tumors showed tracer accumulation with SUVs ranging from 1.2 to 10.0 (mean, 3.8 +/- 2.3; T/B, 3.4 +/- 2.2; tumor/muscle ratio, 7.7 +/- 5.4).
  • Immunohistochemistry confirmed lack of alpha(v)beta3 expression in normal tissue (benign lymph nodes, muscle) and in the two tumors without tracer uptake.
  • [MeSH-major] Galactose / analogs & derivatives. Integrin alphaVbeta3 / analysis. Neoplasms / diagnosis. Peptides, Cyclic. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Microcirculation / pathology. Middle Aged. Tissue Distribution. Tomography, X-Ray Computed / methods

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818691.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Peptides, Cyclic; 0 / fluorogalacto-RGD; X2RN3Q8DNE / Galactose
  •  go-up   go-down


24. Gu LQ, Li FY, Zhao L, Liu Y, Chu Q, Zang XX, Liu JM, Ning G, Zhao YJ: Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma. Endocrine; 2010 Oct;38(2):276-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this cross-sectional study, a total of 62 cases were examined, including 43 patients with PTCs and 19 with benign nodular goiters.
  • In logistic regression analysis, P2X7 receptor expression, tumor size, and capsular infiltration were predictors for lymph node metastasis (P=0.001).
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Female. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Predictive Value of Tests. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 2006 Mar;58(1):58-86 [16507883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7 [16916931.001]
  • [Cites] Endocr Rev. 2007 Dec;28(7):742-62 [17940185.001]
  • [Cites] Purinergic Signal. 2009 Sep;5(3):351-68 [19399640.001]
  • [Cites] Thyroid. 2009 Jan;19(1):21-5 [19072670.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1104-10 [11378340.001]
  • [Cites] J Endocrinol Invest. 2002 Dec;25(11):959-66 [12553555.001]
  • [Cites] Cancer Lett. 2010 Sep 1;295(1):110-23 [20236757.001]
  • [Cites] World J Surg. 2007 Nov;31(11):2085-91 [17885787.001]
  • [Cites] Endocrinology. 2008 Jan;149(1):389-96 [17947359.001]
  • [Cites] J Biol Chem. 2009 Apr 10;284(15):10120-8 [19204004.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):3877-83 [16547218.001]
  • [Cites] Histopathology. 2004 Mar;44(3):206-15 [14987223.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):695-8 [19017759.001]
  • [Cites] J Biol Chem. 2009 Dec 11;284(50):34553-60 [19854829.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Apoptosis. 2001 Aug;6(4):253-61 [11445667.001]
  • [Cites] Endocrinology. 2005 Jul;146(7):3172-8 [15790728.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1862-8 [11280739.001]
  • [Cites] Nature. 2009 Aug 20;460(7258):1035-9 [19626005.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11135-42 [11150303.001]
  • [Cites] Exp Cell Res. 2002 Oct 1;279(2):277-90 [12243753.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1518-22 [18324441.001]
  • [Cites] Biochem Pharmacol. 2009 Nov 1;78(9):1115-26 [19540829.001]
  • [Cites] Ann Diagn Pathol. 2007 Aug;11(4):235-40 [17630106.001]
  • [Cites] Hum Immunol. 2010 Aug;71(8):818-25 [20493226.001]
  • [Cites] Cancer Immunol Immunother. 2004 Sep;53(9):770-6 [15138717.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(1):1-10 [14997049.001]
  • [Cites] Mol Biol Rep. 2010 Apr;37(4):2037-42 [19649722.001]
  • [Cites] Exp Mol Pathol. 2004 Jun;76(3):253-9 [15126108.001]
  • [Cites] EMBO Rep. 2006 Oct;7(10):988-94 [17016456.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Dec;7(8):785-94 [18220537.001]
  • [Cites] Purinergic Signal. 2009 Jun;5(2):251-6 [19263244.001]
  • [Cites] Nephrol Dial Transplant. 2007 Feb;22(2):386-95 [17040997.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):907-14 [16424024.001]
  • [Cites] Endocr Pathol. 2010 Sep;21(3):149-53 [20506003.001]
  • [Cites] Science. 1996 May 3;272(5262):735-8 [8614837.001]
  • [Cites] J Neurochem. 2000 Sep;75(3):965-72 [10936177.001]
  • [Cites] Indian J Cancer. 2010 Apr-Jun;47(2):206-16 [20448388.001]
  • (PMID = 20972735.001).
  • [ISSN] 1559-0100
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Purinergic P2X7; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


25. Cronin CG, Cashell T, Mhuircheartaigh JN, Swords R, Murray M, O'Sullivan GJ, O'Keeffe D: Bone biopsy of new suspicious bone lesions in patients with primary carcinoma: prevalence and probability of an alternative diagnosis. AJR Am J Roentgenol; 2009 Nov;193(5):W407-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone biopsy of new suspicious bone lesions in patients with primary carcinoma: prevalence and probability of an alternative diagnosis.
  • OBJECTIVE: We sought to assess the probability that a new suspicious bone lesion is an alternative diagnosis, that is, a benign lesion or a second malignant tumor as opposed to metastatic disease from the malignant tumor, in a person with known primary malignant disease.
  • The following parameters were recorded: indication, type of primary cancer, date of diagnosis, complications of biopsy, whether the sample was of diagnostic quality, pathologic finding, and thus whether the primary malignant tumor was concordant with the lesion sampled.
  • Cancer types included those of genitourinary tract, breast, thyroid, gastrointestinal tract, and lung and lymphoma and myeloma.
  • Forty-two of 43 positive biopsy findings (98%) were consistent with the primary malignant tumor.
  • The other positive finding was a new malignant tumor.
  • This new tumor was myelofibrosis in a man with chronic myelocytic leukemia.
  • The primary diagnosis correlated highly with that of the new bone lesion (Spearman's test, R = 0.842; p < 0.001).
  • CONCLUSION: In a patient with known primary malignant disease, the probability is low (2%) that biopsy of a new suspicious bone lesion will show the lesion is other than metastasis from the primary tumor.
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Prevalence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843719.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, Kubista E, Czerwenka K: Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep; 2006 Feb;15(2):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Protein expression was, however, considerably less frequent in normal breast (18%), lung (16%) and ovarian (12%) tissues.
  • In contrast to their corresponding benign tissues, pCrkL expression was significantly more common in breast cancer samples (49%, p<0.0001; Fisher's exact test), lung carcinomas (55%, p=0.0002), lymphatic tissues (80% vs. 10%, p=0.012), skin cancer (67%, p=0.020), ovarian malignomas (50%, p<0.0001) and colon carcinomas (63%, p<0.03).
  • We hypothesize that pCrkL is selectively up-regulated in a number of malignant tumor entities and involved in malignant transformation.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / biosynthesis. Biomarkers, Tumor / analysis. Neoplasms / drug therapy. Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / drug effects
  • [MeSH-minor] Benzamides. Blotting, Western. Cell Line, Tumor. Enzyme Activation / drug effects. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Up-Regulation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391854.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / CRKL protein; 0 / Nuclear Proteins; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


27. Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, Pavlovich C, Jankowiak R: Potential biomarker for early risk assessment of prostate cancer. Prostate; 2006 Oct 1;66(14):1565-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This damage leads to mutations that can initiate breast and prostate cancer.
  • To determine whether this damage occurs in humans, urine samples from men with prostate cancer and benign urological conditions, and healthy controls were analyzed.
  • RESULTS: 4-OHE1-1-N3Ade was detected at higher levels in samples from subjects with prostate cancer (n = 7) and benign urological conditions (n = 4) compared to healthy males (n = 5).
  • [MeSH-major] Biomarkers, Tumor / urine. DNA Adducts / urine. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / urine
  • [MeSH-minor] Antibodies, Monoclonal. Early Diagnosis. Electrophoresis, Capillary. Estradiol / analogs & derivatives. Estradiol / chemistry. Estradiol / immunology. Estradiol / urine. Estrogens, Catechol. Humans. Hydroxyestrones / chemistry. Hydroxyestrones / immunology. Hydroxyestrones / urine. Male. Risk Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16894534.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / PHS HHS / / 1 P20 RP15563; United States / NCI NIH HHS / CA / 2P01 CA49210-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / DNA Adducts; 0 / Estrogens, Catechol; 0 / Hydroxyestrones; 3131-23-5 / 4-hydroxyestrone; 4TI98Z838E / Estradiol; C3ZO03450E / 4-hydroxyestradiol
  •  go-up   go-down


28. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CS: Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev; 2007 Feb;16(2):308-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Adiponectin, an adipocyte-secreted hormone with insulin-sensitizing effects, has been inversely associated with several hormonally dependent malignancies, including breast, endometrial, and colorectal cancer.
  • EXPERIMENTAL DESIGN: We collected plasma samples and covariate data in the context of a case-control study of 300 Greek men, including 75 prostate cancer cases, 75 patients with benign prostatic hyperplasia (BPH), and 150 healthy controls.
  • Malignant prostate tissue samples have reduced expression of adiponectin receptors as compared with benign prostate tissue.
  • [MeSH-major] Adiponectin / blood. Biomarkers, Tumor / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Aged. Analysis of Variance. Case-Control Studies. Chi-Square Distribution. Greece / epidemiology. Humans. Immunoenzyme Techniques. Logistic Models. Male. Middle Aged. Receptors, Adiponectin. Risk Factors


29. Shukla S, Shukla M, Maclennan GT, Fu P, Gupta S: Deregulation of FOXO3A during prostate cancer progression. Int J Oncol; 2009 Jun;34(6):1613-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forkhead box transcription factor FOXO3A, an important regulator of cellular function, is thought to act as a tumor suppressor.
  • Similar findings were noted in prostate tumor specimens, in which marked cytoplasmic accumulation of FOXO3A and 14-3-3 in prostate tumors was observed with increasing Gleason grade, in contrast to exclusively nuclear accumulation in benign prostate cells.
  • These findings correlate with decreased FOXO3A DNA binding activity along with down-modulation of FOXO3A transcriptional activity with increasing tumor grade.
  • Our findings demonstrate that tumor associated alterations and redistribution of FOXO3A are frequent events in the etiology of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):25046-51 [10837473.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):189-99 [18845647.001]
  • [Cites] Biochem Soc Trans. 2003 Feb;31(Pt 1):292-7 [12546704.001]
  • [Cites] J Cell Biol. 2004 Jan 19;164(2):175-84 [14734530.001]
  • [Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]
  • [Cites] Biochem J. 2004 Jun 1;380(Pt 2):297-309 [15005655.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4622-9 [14962911.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1543-56 [15509525.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4291-6 [10485474.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):163-9 [15798096.001]
  • [Cites] Prostate. 2005 Aug 1;64(3):224-39 [15712212.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):908-13 [15917664.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33558-65 [16061480.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1062-9 [16424042.001]
  • [Cites] Endocrinology. 2006 May;147(5):2383-91 [16455781.001]
  • [Cites] Nature. 2006 May 25;441(7092):523-7 [16680151.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6998-7006 [16849544.001]
  • [Cites] Nat Cell Biol. 2006 Oct;8(10):1064-73 [16964248.001]
  • [Cites] Exp Gerontol. 2006 Oct;41(10):910-21 [16934425.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2211-20 [17132628.001]
  • [Cites] Cell. 2007 Jan 26;128(2):309-23 [17254969.001]
  • [Cites] Proteins. 2007 May 1;67(2):479-89 [17256767.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):835-42 [17491598.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1940-57 [17536007.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1424-32 [17551921.001]
  • [Cites] Hum Pathol. 2007 Oct;38(10):1501-7 [17597184.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):847-59 [17943136.001]
  • [Cites] Oncogene. 2007 Dec 6;26(55):7647-55 [17563745.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):138-48 [18204439.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2276-88 [18391970.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2312-9 [18391973.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2320-36 [18391974.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2351-63 [18391977.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R21 [18312651.001]
  • [Cites] Biochem Soc Trans. 2002 Aug;30(4):391-7 [12196101.001]
  • (PMID = 19424579.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108512-05; United States / NCI NIH HHS / CA / R01 CA108512; United States / NCI NIH HHS / CA / CA108512; United States / NCI NIH HHS / CA / R01 CA108512-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / DNA, Neoplasm; 0 / FOXO1 protein, human; 0 / FOXO3 protein, human; 0 / FOXO4 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA, Messenger; 0 / Transcription Factors; EC 1.15.1.1 / Superoxide Dismutase; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS105459; NLM/ PMC2683383
  •  go-up   go-down


30. Gratz S, Kempke B, Kaiser W, Behr TM, Pfestroff A, Höffken H: Unexpected 99mTc-tetrofosmin findings during myocardial perfusion scintigraphy: intraindividual comparison with PET/computed tomography. Nucl Med Commun; 2008 Nov;29(11):963-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report six patients found with unexpected mediastinal and thoracic tumor uptake during Tc-tetrofosmin myocardial perfusion scintigraphy (MPS).
  • Subsequently, the patients underwent resection of a thymoma (n=2), nonsmall cell lung cancer (n=1) and breast cancer (n=3).
  • In the patients with breast cancer one was a male patient with ductal, invasive breast cancer.
  • Benign thymomas showed high 99mTc-tetrofosmin ROI >4.0 and low F-FDG SUVmax <2.0, whereas low 99mTc-tetrofosmin ROI <2.0 were found in nonsmall cell lung cancer and breast cancer and high F-FDG SUVmax >2.5 in these malignant tumors.
  • [MeSH-minor] Aged. Breast Neoplasms, Male / complications. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / complications. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Female. Humans. Lung Neoplasms / complications. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Male. Middle Aged. Myocardial Perfusion Imaging / methods. Positron-Emission Tomography / methods. Thymoma / complications. Thymoma / radiography. Thymoma / radionuclide imaging. Thymus Neoplasms / complications. Thymus Neoplasms / radiography. Thymus Neoplasms / radionuclide imaging. Tomography, Emission-Computed. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836374.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


31. Dragoumis D, Atmatzidis S, Chatzimavroudis G, Lakis S, Panagiotopoulou K, Atmatzidis K: Benign spindle cell tumor not otherwise specified (NOS) in a male breast. Int J Surg Pathol; 2010 Dec;18(6):575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign spindle cell tumor not otherwise specified (NOS) in a male breast.
  • Breast spindle cell tumors (BSCTs), although uncommon, constitute a heterogeneous group of benign and malignant lesions, often necessitating different therapeutic approaches.
  • This study describes the case of a 62-year-old man who displayed a gradually growing retroareolar tumor of the left breast.
  • Diverse histological results and immunohistochemical features established the diagnosis of benign BSCT, not otherwise specified.
  • This case report adds to the spectrum of the benign BSCTs and delineates the nature of different types of these lesions, in order to carefully select optimal therapeutic regimes.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064588.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Fotopoulos AD, Alexiou GA, Goussia A, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Tsiouris S: (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index. J Neurooncol; 2008 Sep;89(2):225-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated prospectively whether (99m)Tc-Tetrofosmin ((99m)Tc-TF) uptake in meningiomas correlates with cellular proliferative activity and with tumor grade.
  • In the excised tumor specimens we assessed Ki-67 antigen expression.
  • 14 of 18 patients had benign meningiomas, while the remaining four had anaplastic meningiomas.
  • A significant correlation was found between both (99m)Tc-TF uptake and tumor grade (r = 0.722, P = 0.001) and between (99m)Tc-TF uptake and Ki-67 expression (r = 0.930, P < 0.001).
  • There was a significant correlation between the intensity of tracer uptake and tumor recurrence at 1 year postoperative (r = 0.574, P = 0.02).
  • This pilot study implies that (99m)Tc-TF brain SPECT could prove useful in differentiating benign from anaplastic meningiomas and is a potential indicator of their proliferative activity.
  • [MeSH-minor] Aged. Cell Proliferation. Female. Humans. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Statistics as Topic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1987 Apr;27(4):319-22 [3824137.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):209-14 [15072469.001]
  • [Cites] Adv Anat Pathol. 2005 May;12(3):144-8 [15900115.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Nov;52(6):609-18 [8229080.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Eur J Nucl Med. 1996 Nov;23 (11):1478-84 [8854846.001]
  • [Cites] Neurosurgery. 1992 Apr;30(4):494-7; discussion 497-8 [1584346.001]
  • [Cites] Cancer. 1994 Oct 1;74(7):1921-6 [7521787.001]
  • [Cites] Nucl Med Biol. 2000 Apr;27(3):299-307 [10832087.001]
  • [Cites] Neurol Res. 1999 Oct;21(7):640-4 [10555183.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):970-5 [11567227.001]
  • [Cites] Nucl Med Commun. 2000 Sep;21(9):803-10 [11065152.001]
  • [Cites] J Nucl Med. 1993 Dec;34(12 ):2091-4 [8254393.001]
  • [Cites] J Neurooncol. 2000;46(1):63-70 [10896206.001]
  • [Cites] Curr Opin Oncol. 1997 May;9(3):230-4 [9229144.001]
  • [Cites] Cancer. 1999 May 15;85(10):2249-54 [10326705.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Aug;19(4):411-21 [15453956.001]
  • [Cites] Ann Nucl Med. 1997 Nov;11(4):285-90 [9460519.001]
  • [Cites] Nucl Med Commun. 1998 Feb;19(2):97-105 [9548192.001]
  • [Cites] J Nucl Cardiol. 1995 Jul-Aug;2(4):317-26 [9420806.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):989-93 [3409179.001]
  • [Cites] Neurosurgery. 1995 Sep;37(3):478-82; discussion 483 [7501113.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):820-7 [15785954.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):639-49 [12579319.001]
  • [Cites] Cancer. 1994 Dec 15;74(12):3176-89 [7982181.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Nucl Med. 1993 Dec;34(12 ):2085-9 [8254391.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1036-44; discussion 1044-5 [7885547.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):373-85 [1503912.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):293-6; discussion 296-7 [16953450.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):945-52 [15937304.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] J Neurooncol. 2008 Feb;86(3):359-60 [17634740.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:108-11 [8738510.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Br J Neurosurg. 2004 Aug;18(4):357-61 [15702834.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):153-7 [9261740.001]
  • [Cites] Breast Cancer Res. 2004;6(2):R56-62 [14979918.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Jun;20(3):249-59 [15989470.001]
  • [Cites] Ann Nucl Med. 2007 Jul;21(5):293-8 [17634847.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(1):26-31; discussion 31-2 [9522904.001]
  • [Cites] Expert Rev Med Devices. 2005 Mar;2(2):191-6 [16293055.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):373-80 [8625247.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):207-8 [16575536.001]
  • [Cites] Neuro Oncol. 2008 Feb;10 (1):104-5 [18055861.001]
  • [Cites] J Nucl Med. 1998 May;39(5):802-6 [9591579.001]
  • (PMID = 18458817.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


33. Da Ines D, Petitcolin V, Lannareix V, Montoriol P, Joubert Zakeyh J, Boyer L, Garcier J: [Liver capsule retraction adjacent to a circumscribed liver lesion: review of 26 cases with histological confirmation]. J Radiol; 2009 Sep;90(9 Pt 1):1067-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Rétraction capsulaire hépatique en regard d'une lésion circonscrite: à propos de 26 patients avec preuve histologique.
  • PURPOSE: To review the histological features of 26 circumscribed liver lesions associated with liver capsule retraction and discuss the differential diagnosis while evaluating for the presence of fibrous stromal reaction.
  • RESULTS: Twenty-one patients had benign or malignant liver tumors and 5 patients had confluent hepatic fibrosis.
  • Twenty of 21 liver tumors were malignant (95.2%): 3 intra-hepatic cholangiocarcinoma, 17 cases of metastatic disease including colorectal carcinoma (n=8), bronchogenic carcinoma (n=1), pancreatic carcinoma (n=4), esophageal carcinoma (n=1), breast carcinoma (n=1), gallbladder carcinoma (1) and endocrine neoplasm of the pancreas (n=1), and 1 case of liver sclerosing angioma (n=1).
  • In keeping with previous reports, metastases were frequently the cause and intrahepatic cholangiocarcinoma was the most frequent primary tumor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Radiol. 2009 Sep;90(9 Pt 1):1019-20 [19752803.001]
  • (PMID = 19752810.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


34. Li JS, Sun GW, Wei XY, Tang WH: Expression of periostin and its clinicopathological relevance in gastric cancer. World J Gastroenterol; 2007 Oct 21;13(39):5261-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry was performed to localize and quantify the expression of periostin in benign gastric diseases and gastric cancer, and immunostaining results were correlated with gastric cancer pathological stages.
  • Immunohistochemical staining revealed that periostin was overexpressed in primary gastric cancer, as well as in metastatic lymph nodes, but only faint staining was found in benign gastric ulcers.
  • By quantitative analysis of the immunostaining results, periostin expression was increased 2.5-4-fold in gastric cancer, compared to that in benign gastric disease, and there was a trend toward increasing periostin expression with tumor stage.
  • [MeSH-minor] Aged. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Stomach / metabolism. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876898.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC4171309
  •  go-up   go-down


35. Ferbeyre-Binelfa L, Ramírez-Bollas J, Bautista-Piña V, Espejo-Fonseca R, Ruvalcaba-Limón E, Serratos-Garduño E: [Fibromatosis of the breast. Report of two cases and review of the literature]. Cir Cir; 2009 Jul-Aug;77(4):313-8; 291-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fibromatosis of the breast. Report of two cases and review of the literature].
  • BACKGROUND: Fibromatosis is a term used to describe a group of lesions characterized by well-differentiated fibroblast proliferation with an usually benign biological behavior but with an infiltrative pattern of growth, frequently recurrent and locally invasive.
  • The presence of this entity in breast tissue is an uncommon clinical situation, comprising approximately 0.2% of breast tumors and very often misdiagnosed as malignant disease or phyllodes tumor.
  • In this rare condition, immunohistochemistry is an important diagnostic tool in anatomopathological differential diagnosis with other spindle cell tumors of the breast.
  • CLINICAL CASES: We present two cases of breast fibromatosis confirmed immunohistochemically and also by biopsy.
  • One case had the clinical and imaging appearance of breast carcinoma with the classic irregular mass presentation and the other case was misdiagnosed as phyllodes tumor because of the size and density of the tumor and the cytology.
  • CONCLUSIONS: Approximately 83 cases of breast fibromatosis have been reported during the last 30 years, including one male patient.
  • We reviewed clinicopathological features of two cases of fibromatosis of the breast treated at our institute.
  • [MeSH-major] Breast Neoplasms / diagnosis. Fibroma / diagnosis

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919794.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 44
  •  go-up   go-down


36. Chou SH, Tseleni-Balafouta S, Moon HS, Chamberland JP, Liu X, Kavantzas N, Mantzoros CS: Adiponectin receptor expression in human malignant tissues. Horm Cancer; 2010 Jun;1(3):136-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no difference in the expression of adiponectin receptors or their mRNA between malignant and benign kidney tissue specimens.
  • Overall, there were no correlations between expression of adiponectin receptors or their mRNA and tumor prognostic factors.
  • [MeSH-minor] Adult. Aged. Blotting, Western. Carcinoma, Renal Cell / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Male. Middle Aged. Obesity / complications. Obesity / metabolism. RNA, Messenger / analysis. Real-Time Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s858-66 [18265479.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):993-7 [12629074.001]
  • [Cites] Int J Colorectal Dis. 2009 Mar;24(3):275-81 [18979105.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81 [14983034.001]
  • [Cites] Oncology. 2007;73(3-4):261-9 [18424891.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83 [10092513.001]
  • [Cites] Int J Oncol. 2009 Feb;34(2):339-44 [19148467.001]
  • [Cites] Dig Dis Sci. 2008 Mar;53(3):597-605 [17763959.001]
  • [Cites] Cancer Lett. 2010 Feb 28;288(2):177-82 [19646806.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Endocrinology. 2010 Jan;151(1):115-22 [19887569.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Jpn J Clin Oncol. 2008 Feb;38(2):106-11 [18245516.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):79-87 [15936715.001]
  • [Cites] Breast Cancer Res Treat. 2008 Dec;112(3):405-10 [18163210.001]
  • [Cites] Maturitas. 2009 Jul 20;63(3):253-6 [19524379.001]
  • [Cites] Int J Cancer. 1993 Oct 21;55(4):555-61 [8406981.001]
  • [Cites] Clin Sci (Lond). 2002 Aug;103(2):137-42 [12149104.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):395-403 [12884914.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):43-50 [18313838.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 [11572954.001]
  • [Cites] Obstet Gynecol Surv. 2005 Oct;60(10):683-92 [16186785.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6365-78 [15322511.001]
  • [Cites] Obesity (Silver Spring). 2006 Jan;14(1):28-35 [16493120.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8 [17192291.001]
  • [Cites] Trends Pharmacol Sci. 2005 Feb;26(2):69-76 [15681023.001]
  • [Cites] Lancet. 2008 Feb 16;371(9612):569-78 [18280327.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1430-6 [17512191.001]
  • [Cites] Oncol Rep. 2008 Oct;20(4):971-7 [18813842.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):18341-7 [15734737.001]
  • [Cites] Int J Hematol. 2008 Nov;88(4):374-80 [18818986.001]
  • [Cites] J Clin Pathol. 2009 Aug;62(8):705-9 [19638541.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):140-6 [17036323.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):289-99 [18310295.001]
  • [Cites] BMJ. 2007 Dec 1;335(7630):1134 [17986716.001]
  • [Cites] Eur Urol. 2008 Oct;54(4):866-73 [18343565.001]
  • [Cites] Int J Obes (Lond). 2007 Dec;31(12):1843-8 [17607322.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1573-8 [17205522.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1160-3 [15001602.001]
  • [Cites] Anticancer Res. 2009 Aug;29(8):3321-7 [19661351.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):432-6 [8621222.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):814-21 [12910527.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Gut. 2008 Nov;57(11):1531-8 [18676419.001]
  • [Cites] Lung Cancer. 2008 Sep;61(3):391-7 [18342391.001]
  • [Cites] Cancer Causes Control. 2009 Jul;20(5):625-33 [19051043.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):308-13 [17301264.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1214-21 [18483344.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1120-7 [17459059.001]
  • (PMID = 21761356.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Adiponectin
  •  go-up   go-down


37. He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T, Skog S: Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep; 2005 Oct;14(4):1013-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigate thymidine kinase 1 concentration in serum (S-TK1) as a potential tumor marker.
  • S-TK1 concentration and STK activity levels were determined in 9 human malignant diseases (breast, gastric, rectal, colorectal, lung, brain cancer, hepatoma, lymphoma, leukaemia) and in benign and non-cancerous diseases, representing 850 preoperative cases.
  • S-TK1 concentrations and STK activity levels in preoperative malignant patients were significantly higher than in healthy individuals, in patients with benign tumors and in those with non-cancerous diseases.
  • Significant correlations between concentration and activity level were only found in healthy individuals, in patients with benign tumors, and in some patients with malignancies, i.e. leukaemia, and breast and gastric cancers.
  • We conclude that S-TK1 concentration is a more sensitive tumor marker in solid malignancies than is STK activity.
  • [MeSH-major] Biomarkers, Tumor. Neoplasms / blood. Neoplasms / diagnosis. Thymidine Kinase / blood
  • [MeSH-minor] Breast Neoplasms / pathology. Cell Line, Tumor. Cell Proliferation. Dose-Response Relationship, Drug. Female. Humans. Male. Neoplasm Staging. Radioimmunoassay / methods. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142366.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1
  •  go-up   go-down


38. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ: Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem; 2008 Jan;54(1):44-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
  • METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1576-8 [12381711.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):203-9 [14499014.001]
  • [Cites] BMC Bioinformatics. 2003 Jun 9;4:24 [12795817.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Dis Markers. 2003-2004;19(4-5):185-95 [15258333.001]
  • [Cites] Clin Chem. 2004 Dec;50(12):2398-401 [15563493.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):142-9 [15685197.001]
  • [Cites] Clin Chem. 2005 Aug;51(8):1525-8 [15951319.001]
  • [Cites] Clin Chem. 2005 Sep;51(9):1637-49 [16002455.001]
  • [Cites] Proteomics. 2006 Mar;6(5):1676-80 [16447157.001]
  • [Cites] Clin Chem. 2006 Apr;52(4):771-2; author reply 772 [16595832.001]
  • [Cites] Proteomics. 2006 May;6(10):3189-98 [16586434.001]
  • [Cites] Clin Chem. 2006 Jul;52(7):1218-22 [16675505.001]
  • [Cites] Biometrics. 2006 Jun;62(2):589-97 [16918924.001]
  • [Cites] J Proteome Res. 2006 Sep;5(9):2079-82 [16944917.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Feb;3(2):96-103 [17299447.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):645-56 [17303688.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5114-23 [16097747.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3262-77 [16052621.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1835-43 [12324514.001]
  • [CommentIn] Clin Chem. 2008 Jan;54(1):3-5 [18160722.001]
  • [CommentIn] Clin Chem. 2008 Jan;54(1):6-7 [18160723.001]
  • (PMID = 17981926.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 084986; United States / NCI NIH HHS / CA / CA 84968; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / CA 86368; United States / NCI NIH HHS / CA / U01 CA086402; United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / U01 CA086323; United States / NCI NIH HHS / CA / U24 CA086368; United States / NCI NIH HHS / CA / U01 CA086368; United States / NCI NIH HHS / CA / CA 86359; United States / NCI NIH HHS / CA / CA 86402; United States / NCI NIH HHS / CA / U24 CA086359; United States / NCI NIH HHS / CA / CA 86323; United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / CA 85067; United States / NCI NIH HHS / CA / U01 CA084986
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS371877; NLM/ PMC3354530
  •  go-up   go-down


39. Suh JH, Gardner JM, Kee KH, Shen S, Ayala AG, Ro JY: Calcifications in prostate and ejaculatory system: a study on 298 consecutive whole mount sections of prostate from radical prostatectomy or cystoprostatectomy specimens. Ann Diagn Pathol; 2008 Jun;12(3):165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although calcifications in the prostate are a common manifestation, the relationship between calcifications and prostate cancer is not clearly documented as in breast cancer.
  • The prostatic calcifications occurred mostly in benign glands and/or stroma of all zones and the verumontanum.
  • There were 4 cases of prostatic calcifications in the areas of prostatic adenocarcinoma: 3 cases with calcifications in the tumor glands and 1 case with calcifications in tumor stroma but not in the accompanying tumor glands.
  • In conclusion, calcifications are a very common finding in prostatectomy specimens and seem mostly to be associated with benign prostatic hyperplasia.
  • However, calcifications can occur in direct association with prostatic adenocarcinoma, although the incidence of this association is not as high as in breast carcinoma.
  • [MeSH-minor] Adult. Aged. Cystectomy. Humans. Male. Middle Aged. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486891.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Koh YW, Kim JW, Lee SW, Choi EC: Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions. Surg Endosc; 2009 Sep;23(9):2053-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions.
  • Recently, the authors developed a unilateral axillo-breast approach for endoscopic hemithyroidectomy to minimize the visible scar in a natural position and to overcome the limitation of instrumentation.
  • METHODS: This study enrolled 52 consecutive patients undergoing endoscopic hemithyroidectomy via a unilateral axillo-breast approach without gas insufflation.
  • A second 1.0-cm skin incision was made along the upper margin of the mammary areola on the tumor side for insertion of a 12-mm trocar.
  • RESULTS: Postoperative pathology showed 11 follicular adenomas, 1 follicular carcinoma, and 40 benign thyroid lesions.
  • CONCLUSION: Although the aspect of invasiveness could be improved, endoscopic hemithyroidectomy via a unilateral axillo-breast approach without gas insufflation is safe and effective and appears to provide better cosmetic results and a shorter operation time than other endoscopic methods for managing selective unilateral benign thyroid lesions.
  • [MeSH-minor] Adenocarcinoma, Follicular / surgery. Adolescent. Adult. Axilla. Breast. Drainage. Feasibility Studies. Female. Hematoma / etiology. Humans. Length of Stay. Male. Middle Aged. Postoperative Complications / etiology. Seroma / etiology. Vocal Cord Paralysis / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2008 Jan;22(1):154-7 [17440778.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2006 Aug;16(4):226-31 [16921301.001]
  • [Cites] Surg Endosc. 2007 Dec;21(12):2166-71 [17479328.001]
  • [Cites] Surg Endosc. 2002 Dec;16(12 ):1741-5 [12140635.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):286-9 [11943128.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):82-5 [11044518.001]
  • [Cites] Surgery. 1997 Nov;122(5):893-901 [9369889.001]
  • [Cites] Anesth Analg. 1997 May;84(5):1154-6 [9141952.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):891-900 [17289376.001]
  • [Cites] World J Surg. 2007 Mar;31(3):601-6 [17308853.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Jun;13(3):196-201 [12819505.001]
  • [Cites] Surg Endosc. 1997 Aug;11(8):877 [9266657.001]
  • [Cites] Arch Surg. 2002 Mar;137(3):301-4; discussion 305 [11888453.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2007 Feb;17(1):21-5 [17362173.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Feb;13(1):20-5 [12598753.001]
  • [Cites] J Surg Oncol. 1994 Dec;57(4):235-8 [7990478.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2302-6; discussion 2307-8 [17566819.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Aug;11(4):268-72 [11525373.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4 [10872517.001]
  • [Cites] J Am Coll Surg. 1999 Jun;188(6):697-703 [10359365.001]
  • (PMID = 18528625.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Lauwers K, Bestman TJ, Bergmans G, Molderez C: Granular cell tumour of the male breast. Acta Chir Belg; 2008 Jan-Feb;108(1):112-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumour of the male breast.
  • Granular cell tumour (GCT) is a rare neoplasm that can be found in multiple sites throughout the body.
  • Occasionally GCT is located in the breast.
  • In general, it appears as a singular benign lesion, although it can be multi-focal and rare cases with malignant behaviour have been reported.
  • We report a rare case of granular cell tumour of the nipple in the male breast, treated by wide local excision.
  • [MeSH-major] Breast Neoplasms, Male / surgery. Granular Cell Tumor / surgery
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Male. Nipples

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18411585.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


43. Magro G: Epithelioid-cell myofibroblastoma of the breast: expanding the morphologic spectrum. Am J Surg Pathol; 2009 Jul;33(7):1085-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid-cell myofibroblastoma of the breast: expanding the morphologic spectrum.
  • Myofibroblastoma (MFB) of the breast is an uncommon benign tumor, which exhibits a wide variety of cytomorphologic features and architectural patterns.
  • All but 1 case contained an intratumoral mature fatty component that variably accounted from 10% to 40% of the entire tumor.
  • Immunohistochemistry, revealing a variable coexpression of vimentin, desmin, alpha-smooth muscle actin, CD34, bcl-2 protein, CD99, CD10, estrogen/progesterone/androgen receptors, is crucial in confirming the diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms, Male / pathology. Neoplasms, Muscle Tissue / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Epithelioid Cells / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19390423.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


44. Böttger T, Terzic A, Müller M: [Laparoscopic pancreatic resection]. Zentralbl Chir; 2006 Aug;131(4):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In all four cases laparoscopic distal pancreatic resection was performed for tumor.
  • Histologic examination showed a neuroendocrine carcinoma, a serous-microcystic adenoma, a low differentiated ductal adenocarcinoma and an intraductal papillary-mucinous tumor of borderline type.
  • CONCLUSION: Laparoscopic resection of distal pancreas shows the common benefit of minimal invasive surgery for the early postoperative period and is an attractive alternative for treatment of benign and semimalign pancreatic tumors.
  • [MeSH-major] Adenoma / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Neuroendocrine / surgery. Cystadenoma, Mucinous / surgery. Laparoscopy. Pancreas / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Fundoplication. Gastroesophageal Reflux / surgery. Humans. Length of Stay. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Male. Middle Aged. Minimally Invasive Surgical Procedures. Positron-Emission Tomography. Radiography, Abdominal. Spleen / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004190.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


45. Gerszten PC, Burton SA: Clinical assessment of stereotactic IGRT: spinal radiosurgery. Med Dosim; 2008;33(2):107-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At our institution, we have developed a successful multidisciplinary spinal radiosurgery program in which 542 spinal lesions (486 malignant and 56 benign lesions) were treated with a single-fraction radiosurgery technique.
  • The most common metastatic tumors were renal cell (89 cases), breast (74 cases), and lung (71 cases).
  • The most common benign tumors were neurofibroma (24 cases), schwannoma (13 cases), and meningioma (7 cases).
  • Tumor volume ranged from 0.16 to 298 mL (mean 47 mL).
  • The primary indication for radiosurgery was pain in 326 cases, as a primary treatment modality in 70 cases, for tumor radiographic tumor progression in 65 cases, for post-surgical treatment in 38 cases, for progressive neurological deficit in 35 cases, and as a radiation boost in 8 cases.
  • Long-term tumor control was demonstrated in 90% of lesions treated with radiosurgery as a primary treatment modality and in 88% of lesions treated for radiographic tumor progression.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Equipment Design. Female. Humans. Male. Middle Aged. Stereotaxic Techniques. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18456162.001).
  • [ISSN] 0958-3947
  • [Journal-full-title] Medical dosimetry : official journal of the American Association of Medical Dosimetrists
  • [ISO-abbreviation] Med Dosim
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Dupuis C, Coard KC: A review of granular cell tumours at the University Hospital of the West Indies: 1965-2006. West Indian Med J; 2009 Mar;58(2):138-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are usually benign, but as they are infrequently diagnosed preoperatively, they may be confused clinically with malignant lesions.
  • Of these, 99patients were female and 23 male, providing a male:female ratio of l to 4.3.
  • Lesions ranged in size from 0.2 cm to 10 cm in greatest dimension, the average size being 1.85 cm and were found in a diverse array of anatomic locations, the most common being the vulva, breast and tongue.
  • The correct clinical diagnosis was proffered preoperatively in only one case.
  • In contrast, a malignant diagnosis was suggested in 19 cases.
  • In particular lesions of the tongue accounted for fewer than expected, while lesions of the breast and vulva were considerably increased.
  • [MeSH-major] Granular Cell Tumor / epidemiology. Granular Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms / epidemiology. Child. Child, Preschool. Female. Hospitals, University. Humans. Infant. Infant, Newborn. Male. Middle Aged. Tongue Neoplasms / epidemiology. Vulvar Neoplasms / epidemiology. West Indies / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21866599.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down


47. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z: Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer; 2009;9:40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of PADI4 was investigated in various tumors and non-tumor tissues (n = 1673) as well as in A549, SKOV3 and U937 tumor cell lines by immunohistochemistry, real-time PCR, and western blot.
  • RESULTS: Immunohistochemistry detected significant PADI4 expression in various malignancies including breast carcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cancer cells, colorectal adenocarcinomas, renal cancer cells, ovarian adenocarcinomas, endometrial carcinomas, uterine adenocarcinomas, bladder carcinomas, chondromas, as well as other metastatic carcinomas.
  • However, PADI4 expression was not observed in benign leiomyomas of stomach, uterine myomas, endometrial hyperplasias, cervical polyps, teratomas, hydatidiform moles, trophoblastic cell hyperplasias, hyroid adenomas, hemangiomas, lymph hyperplasias, schwannomas, neurofibromas, lipomas, and cavernous hemangiomas of the liver.
  • Additionally, PADI4 expression was not detected in non-tumor tissues including cholecystitis, cervicitis and synovitis of osteoarthritis, except in certain acutely inflamed tissues such as in gastritis and appendicitis.
  • Quantitative PCR and western blot analysis showed higher PADI4 expression in gastric adenocarcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cell cancers and breast cancers (n = 5 for each disease) than in the surrounding healthy tissues.
  • Furthermore, western blot analysis detected PADI4 expression in cultured tumor cell lines.
  • ELISA detected increased PADI4 and cAT levels in the blood of patients with various malignant tumors compared to those in patients with chronic inflammation and benign tumors.
  • Additionally, PADI4 and cAT levels were significantly associated with higher levels of known tumor markers.
  • [MeSH-major] Hydrolases / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Antithrombins / metabolism. Blotting, Western. Cell Line, Tumor. Citrulline / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation. Male. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 1998 May-Jun;84(3):364-7 [9678618.001]
  • [Cites] Pathologe. 1996 Nov;17(6):425-32 [9082363.001]
  • [Cites] J Cell Mol Med. 2004 Oct-Dec;8(4):498-508 [15601578.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):235-40 [15704650.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):293-8 [15561738.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):309-18 [15907383.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42 [16365013.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):76-80 [17826626.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1682-9 [18350599.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):475-83 [18509000.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]
  • [Cites] Mol Cell Biol. 2008 Aug;28(15):4745-58 [18505818.001]
  • [Cites] Adv Exp Med Biol. 2008;630:112-32 [18637488.001]
  • [Cites] Histopathology. 2001 Jan;38(1):62-7 [11135048.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):486-92 [11973607.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):173-7 [12023846.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):201-7 [12023851.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):395-402 [12833157.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):385-405 [15212335.001]
  • [Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):579-82 [2114816.001]
  • [Cites] APMIS. 1991 Nov;99(11):981-8 [1720319.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(3):209-15 [1384221.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):793-806 [7686887.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):767-72 [9843169.001]
  • (PMID = 19183436.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antithrombins; 0 / Neoplasm Proteins; 29VT07BGDA / Citrulline; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
  • [Other-IDs] NLM/ PMC2637889
  •  go-up   go-down


48. Kara C, Kutlu AO, Tosun MS, Apaydin S, Senel F: Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone. Horm Res; 2005;63(5):252-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
  • Peutz-Jeghers syndrome (PJS) is a rare disorder characterized by benign intestinal hamartomatous polyps and mucocutaneous pigmentation, and with an increased risk for intestinal and extra-intestinal neoplasms.
  • We report on a 7.25-year-old boy with PJS, bilateral gynecomastia, Sertoli cell tumor and nephrocalcinosis, and present the outcome of 1-year treatment with the aromatase inhibitor testolactone.
  • The patient presented with bilateral breast and testis enlargement, and mucocutaneous pigmentation.
  • One-year treatment with testolactone reduced the breast base diameter from 7 to 3 cm, and bone age advanced 1.2 years during this period.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Gynecomastia / complications. Peutz-Jeghers Syndrome / complications. Sertoli Cell Tumor / complications. Testicular Neoplasms / complications. Testolactone / therapeutic use
  • [MeSH-minor] Child. Humans. Male. Nephrocalcinosis / complications

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. TESTOLACTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947469.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 6J9BLA949Q / Testolactone
  •  go-up   go-down


49. Belizon A, Balik E, Horst P, Feingold D, Arnell T, Azarani T, Cekic V, Skitt R, Kumara S, Whelan RL: Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection. Surg Endosc; 2008 Feb;22(2):287-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because VEGF is a potent promoter of angiogenesis, which is critical to tumor growth, a sustained increase in blood VEGF levels after surgery may stimulate the growth of residual metastases early after surgery.
  • RESULTS: A total of 49 patients with cancer and 30 patients with benign indications, all of whom underwent minimally invasive colorectal resection, were assessed separately.
  • With regard to the benign patients, the median preoperative VEGF level was 112 pg/ml, and the peak postoperative value, 286 pg/ml, was noted during postoperative week 2.
  • Significant elevations in a similar pattern also were noted for the benign patients.
  • It is possible that the growth of residual tumor deposits may be stimulated early after surgery.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2008 Feb;22(2):285-6 [17973168.001]
  • [Cites] Cancer Detect Prev. 1988;12(1-6):421-9 [3263198.001]
  • [Cites] Surgery. 1999 Jul;126(1):5-9 [10418585.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):564-9 [9593237.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):55-9 [15531967.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):657-62 [11078612.001]
  • [Cites] Anticancer Res. 1992 Sep-Oct;12(5):1603-16 [1444228.001]
  • [Cites] Breast Cancer Res Treat. 2005 Sep;93(1):35-40 [16184456.001]
  • [Cites] Dig Surg. 1998;15(2):102-4 [9845570.001]
  • [Cites] Cytokine. 2004 Jan 21;25(2):68-72 [14693162.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Surg Endosc. 2001 Jun;15(6):600-8 [11591950.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):308-14; discussion 308-14 [12632340.001]
  • [Cites] J Biomed Mater Res A. 2005 Sep 15;74(4):659-65 [16035066.001]
  • [Cites] Cancer. 1970 Feb;25(2):362-7 [5413507.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):270-8 [14716760.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1439-42 [9782033.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):333-8 [10671682.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Lab Clin Med. 2005 Apr;145(4):194-203 [15962838.001]
  • [Cites] Infect Immun. 1997 Jun;65(6):2283-91 [9169765.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):510 [9181567.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):417-23 [11875709.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):874-9 [10543260.001]
  • [Cites] Arch Surg. 1995 Jun;130(6):649-53 [7763175.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1670-4 [15540297.001]
  • [Cites] Gastric Cancer. 2002;5(3):137-41 [12378339.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):36-9 [11961601.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):439-42 [8602242.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] Oncologist. 2007 Mar;12(3):356-61 [17405901.001]
  • [Cites] Surgery. 2002 May;131(5):548-55 [12019409.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Angiogenesis. 1999;3(4):335-44 [14517413.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] J Clin Anesth. 2004 Sep;16(6):435-9 [15567647.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • (PMID = 18204877.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


50. Tamiolakis D, Tsamis I, Thomaidis V, Lambropoulou M, Alexiadis G, Venizelos I, Jivanakis T, Papadopoulos N: Oral complaints caused from metastases to the mandible and maxilla. Chirurgia (Bucur); 2007 Jul-Aug;102(4):439-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of these conditions are of a chronic and benign nature.
  • The most common malignant bone tumor is metastatic carcinoma, and tumors arising in the breast, prostate, thyroid, lung and kidney have a special propensity to spread to bone.
  • Patients presented with oral discomforts disregarding the primary tumor.
  • Physicians who frequently advise patients with oral complaints should keep in mind that whereas these symptoms are mostly of a chronic and benign nature, metastases from a malignant tumor must be included in the differential diagnosis.
  • [MeSH-minor] Aged. Diagnosis, Differential. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / pathology. Male. Medical Records. Middle Aged. Retrospective Studies. Survival Rate. Thyroid Neoplasms / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966942.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


51. Kinkor Z, Havlícek F, Michal M: [Benign mesenchymal stromal tumor of the breast simulating benign schwannoma in an 81-year-old male--a case report]. Cesk Patol; 2006 Oct;42(4):186-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign mesenchymal stromal tumor of the breast simulating benign schwannoma in an 81-year-old male--a case report].
  • [Transliterated title] Benigní vretenobunecný stromální tumor prsu podobný schwannomu u 81letého muze-- kazuistika.
  • Presented is an unusual case of a benign mesenchymal stromal tumor of the breast in an 81-year-old male.
  • The basic appearance of the lesion simulated benign schwannoma and was misinterpreted as a low-grade myxoid liposarcoma initially.
  • Well-circumscribed, gray-white mass measuring 35 mm in maximum diameter was discovered deep in the parenchyma of the completely removed breast.
  • Microscopically, the lesion consisted of myxoid, richly vascular background where dominated oval or spindle cells with impressive palisading replicating that of benign schwannoma.
  • On the background of both detailed review and differential diagnosis of benign, so-called stromal tumor of the female breast, the rarity of this microscopic finding in male is documented.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Liposarcoma, Myxoid / pathology. Neurilemmoma / pathology. Stromal Cells / pathology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17171974.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


52. Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B, Janssen KP: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer; 2006 Nov 20;95(10):1419-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gene SASH1 (SAM- and SH3-domain containing 1) has originally been identified as a candidate tumour suppressor gene in breast cancer.
  • Moreover, nine benign adenomas and 10 liver metastases were analysed.
  • [MeSH-major] Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Colon / metabolism. Colon / pathology. Down-Regulation. Female. Genes, Tumor Suppressor. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):89-93 [11470164.001]
  • [Cites] Cell Immunol. 2005 May;235(1):46-55 [16137664.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5373-7 [11536050.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):137-41 [11594764.001]
  • [Cites] Nat Struct Biol. 2002 Jun;9(6):453-7 [11992127.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2972-83 [12771949.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):369-80 [12800148.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):737-47 [15381729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1995 Feb 16;373(6515):573-80 [7531822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9646-60 [16227612.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):4173-82 [11483520.001]
  • (PMID = 17088907.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SASH1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2360597
  •  go-up   go-down


53. Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, Sanlioglu S: Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol; 2007 Jan;177(1):359-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of TRAIL and its receptors in benign and malignant prostate tissues.
  • PURPOSE: Because TRAIL (tumor necrosis factor related apoptosis inducing ligand) selectively kills cancer cells without damaging normal cells, a gene therapy approach using TRAIL is feasible for treating patients with cancer.
  • Our recent studies suggest that TRAIL receptor composition is the major modulator of TRAIL sensitivity, as demonstrated using prostate, breast and lung cancer cells.
  • MATERIALS AND METHODS: Paraffin embedded prostate tissues of 44 patients with benign prostatic hyperplasia, 28 with organ confined prostate carcinoma and 26 with advanced prostate carcinoma were analyzed using immunohistochemical staining procedures.
  • RESULTS: Significant levels of TRAIL-R4 decoy receptor expression were detected in patients with benign prostatic hyperplasia, and organ confined and advanced prostate carcinoma.
  • All TRAIL markers tested appear to be valuable markers for separating patients with benign prostatic hyperplasia from patients with organ confined prostate carcinoma or advanced prostate carcinoma.
  • [MeSH-minor] Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162091.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand
  •  go-up   go-down


54. Mohri Y, Mohri T, Wei W, Qi YJ, Martin A, Miki C, Kusunoki M, Ward DG, Johnson PJ: Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer. Br J Cancer; 2009 Jul 21;101(2):295-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI) and antibody arrays were used to compare protein expression in 21 pairs of gastric cancer tissue and adjacent normal mucosa and serum from 51 gastric cancer patients and 29 patients with benign gastric diseases.
  • Macrophage migration inhibitory factor (MIF) was increased five-fold (P=1.84 x 10(-7)) in the serum of gastric cancer patients relative to individuals with benign gastric disease.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2001 Jan;32(1):41-4 [11154168.001]
  • [Cites] Scand J Gastroenterol. 2000 Sep;35(9):950-6 [11063155.001]
  • [Cites] Eur J Clin Invest. 2001 Apr;31(4):337-43 [11298781.001]
  • [Cites] Cancer Lett. 2001 Oct 10;171(2):125-32 [11520595.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):318-22 [11553862.001]
  • [Cites] Helicobacter. 2001 Sep;6(3):216-24 [11683924.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):1061-6 [11668338.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1449-56 [11920501.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):298-304 [11919217.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1311-24 [11943716.001]
  • [Cites] Am J Gastroenterol. 2003 Apr;98(4):735-9 [12738449.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii31-6 [12810455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9354-9 [12878730.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6971-83 [14583499.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):139-44 [14693236.001]
  • [Cites] Am J Clin Pathol. 2008 May;129(5):772-9 [18426738.001]
  • [Cites] J Immunol. 2008 Jun 1;180(11):7338-48 [18490733.001]
  • [Cites] Pathol Oncol Res. 2008 Mar;14(1):79-83 [18347935.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R48 [18510725.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:42-7 [15335412.001]
  • [Cites] Oncology. 1999 Jul;57(1):55-62 [10394126.001]
  • [Cites] Gastric Cancer. 2004;7(4):233-9 [15616771.001]
  • [Cites] BMC Cancer. 2005 Jan 19;5:8 [15656915.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):66-73 [16012935.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1485-503 [16285950.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • [Cites] Gut. 2006 Jun;55(6):797-802 [16488898.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1045-53 [16574760.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1898-905 [16755300.001]
  • [Cites] Immunity. 2006 Oct;25(4):595-606 [17045821.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Lett. 2008 Mar 18;261(2):147-57 [18171602.001]
  • [Cites] J Exp Med. 1999 Nov 15;190(10):1375-82 [10562313.001]
  • [Cites] Am J Surg. 2001 Jan;181(1):16-9 [11248169.001]
  • (PMID = 19550422.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Macrophage Migration-Inhibitory Factors; 0 / Neoplasm Proteins; 0 / alpha-Defensins; 0 / human neutrophil peptide 1; 0 / human neutrophil peptide 2; 0 / human neutrophil peptide 3
  • [Other-IDs] NLM/ PMC2720195
  •  go-up   go-down


55. Abdel Salam I, Gaballa HE, Abdel Wahab N: Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. Med Oncol; 2009;26(2):161-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 30 patients with pathologically proven NSCLC were enrolled in this study in addition to ten normal controls subjects and ten cases with benign pulmonary diseases as broncheicatsis, chronic obstructive pulmonary disease.
  • The levels were significantly higher in those with stages III, IV compared with I, II, and in those with higher grades of the tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / blood. Receptor, ErbB-2 / blood
  • [MeSH-minor] Aged. Bronchoalveolar Lavage Fluid / chemistry. Female. Humans. Male. Middle Aged. Prognosis


56. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B: Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol; 2005 Nov;33(5):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant mesothelioma (MM) is a locally aggressive and highly lethal tumor of serosal cavities that is rarely associated with clinically detectable metastasis to distant organs.
  • Effusions from patients diagnosed with ovarian (=24) and breast (=38) adenocarcinomas and MM (=24) (total = 86) were analyzed for 67-kd LR protein expression, using immunocytochemistry.
  • Protein expression of the 67-kd LR was frequently detected in carcinomas (19/24 ovarian tumors, 79%; 15/38 breast tumors, 39%), but was rare in MM (2/24 cases, 8%), despite the presence of mRNA transcripts for the receptor in all 21 specimens studied using RT-PCR.
  • Nine benign effusions that were additionally studied for protein expression were uniformly negative, as were all reactive mesothelial cells in malignant effusions.
  • Our results suggest that the 67-kd LR may aid in the differential diagnosis between metastatic carcinoma, mainly of ovarian origin, and MM.
  • They additionally suggest that the failure of MM to express the 67-kd LR protein, as opposed to the frequent expression in carcinomas with proven metastatic capacity, may be one of the factors contributing to the reduced ability of the former tumor to metastasize to distant organs.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Female. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240397.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Laminin
  •  go-up   go-down


57. Leinweber B, Chott A, Kerl H, Cerroni L: Epidermotropic precursor T-cell lymphoma with highly aggressive clinical behavior simulating localized pagetoid reticulosis. Am J Dermatopathol; 2007 Aug;29(4):392-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor cells expressed a T-phenotype (CD3+, CD20-) and were CD30-, CD4-, and CD8-negative.
  • A diagnosis of localized pagetoid reticulosis (Woringer-Kolopp disease) with possible large cell transformation was proposed.
  • Reevaluation of the skin lesion and of a tonsil specimen previously interpreted as benign hyperplasia showed features consistent with those observed in the lymph node.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Lymphatic Diseases / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Nipples / pathology. Paget's Disease, Mammary / pathology
  • [MeSH-minor] Adult. Antigens, CD3 / analysis. Antigens, CD43 / analysis. Antigens, CD7 / analysis. Fatal Outcome. Humans. Hyperplasia. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Palatine Tonsil / pathology. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667175.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD43; 0 / Antigens, CD7
  •  go-up   go-down


58. Nese N, Kandiloglu AR, Simsek G, Lekili M, Ozdamar A, Catalkaya A, Coskun T: Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal Quant Cytol Histol; 2010 Apr;32(2):90-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin.
  • RESULTS: HSP47 and fascin were localized to cytoplasm, and HSP47 and fascin IR were higher in IDC and PCa than benign groups (p < 0.05).
  • Fascin expression correlated with estrogen receptor and progesterone receptor negativity, tumor size and stage in IDC and surgical margin status in PCa.
  • Although there is no relationship with recurrence or metastatic status, fascin overexpression correlated with tumor size, which may prompt its use as a prognostic factor in IDC.


59. García-Reyna JC, Rico Martínez G, Vega González IF, Linares LM, Delgado Cedillo EA, Romero Ramírez R: [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin]. Acta Ortop Mex; 2008 Nov-Dec;22(6):390-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin].
  • [Transliterated title] 99mTc-Tetrofosmin en la evaluación de tumores musculoesqueléticos.
  • INTRODUCTION: (99m)Tc-tetrofosmin is an efficient agent as a tumor marker.
  • Several studies have proven its efficiency in detection and localization of tumors of the breast, larynx, thyroid, parathyroid glands, lung, brain, skin, lymphatic and musculoskeletal tissues with a sensitivity and specificity of 95% to 100%.
  • Nevertheless, benign pathology such as active inflammation is a source of false positives and the attending physician must consider the aid of complementary studies such as histopathology.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280840.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


60. Hostanska K, Suter A, Melzer J, Saller R: Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines. Anticancer Res; 2007 Mar-Apr;27(2):873-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Phytotherapy is a third approach for treating lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).
  • MATERIALS AND METHODS: The effect of an ethanolic extract of S. repens (10-1000 microg/ml) was tested in hormone-sensitive LNCaP, MCF-7 and hormone-insensitive DU 145, MDA MB231 prostate, breast carcinoma cell lines, renal Caki-1, urinary bladder J82, colon HCT 116 and lung A 549 cancer cells.
  • In hormone-sensitive prostate LNCaP and breast MCF-7 cell lines, the effect of extract expressed in GI50 was 2.2- and 2.5-fold more potent (p < 0.01) than in hormone-insensitive DU 145 and MDA MB231 cells.
  • [MeSH-minor] Breast Neoplasms / drug therapy. Cell Line, Tumor. Drug Screening Assays, Antitumor. Female. HCT116 Cells. Humans. Male. Neoplasms, Hormone-Dependent / drug therapy. Prostatic Neoplasms / drug therapy


61. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K: High incidence of EMMPRIN expression in human tumors. Int J Cancer; 2006 Oct 15;119(8):1800-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracellular matrix metalloproteinase inducer expressed by tumor cells stimulates peritumoral fibroblasts to produce matrix metalloproteinases, thus contributing to tumor invasion and metastasis.
  • EMMPRIN expression was detected immunohistochemically using monoclonal antibodies MEM-M6/1 and HIM6 and tissue microarrays with 2,348 and 608 tissue samples from 129 distinct tumor types and 76 different normal tissues, respectively.
  • Expression and glycosylation state of EMMPRIN in human breast cancer cells were analyzed by Western blot analysis with monoclonal antibodies recognizing distinct carbohydrate structures and biochemical methods.
  • EMMPRIN expression was found in 112 of 129 tumor entities analyzed with malignant tumors being EMMPRIN positive more frequently than benign tumors.
  • A remarkable heterogeneity in EMMPRIN expression between tumor entities was observed.
  • Among others, squamous-cell carcinomas (60-100%), pancreatic (87%), chromophobic kidney (83%), hepatocellular (83%) or medullary breast (83%) adenocarcinomas as well as glioblastoma multiforme (79%) presented with a particular high incidence of EMMPRIN expression.
  • We could further demonstrate that breast cancer cells expressed EMMPRIN isoforms differing in the presence or absence of Lewis X glycan structures.
  • [MeSH-minor] Carbohydrate Metabolism. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Male. Protein Isoforms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16721788.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


62. Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S, Ishii K, Ikeuchi N, Tsuchida A, Kasuya K, Kawai T, Sakai Y, Moriyasu F: Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg; 2008;15(2):189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result.
  • BACKGROUND/PURPOSE: It has been reported that circulating tumor cells (CTCs) can be used to predict survival in metastatic breast cancer.
  • CTC was negative in 15 patients with PC (stage II, 1; stage III, 1; stage IVa, 7; and stage IVb, 6) and in the subjects with benign conditions.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392713.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


63. Ligr M, Li Y, Zou X, Daniels G, Melamed J, Peng Y, Wang W, Wang J, Ostrer H, Pagano M, Wang Z, Garabedian MJ, Lee P: Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol; 2010 Apr;176(4):1891-900
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer.
  • Here we report that the full length ARA70alpha, in contrast, represses prostate cancer cell proliferation and anchorage-independent growth in vitro and inhibits tumor growth in nude mice xenograft experiments in vivo.
  • The tumor suppressor function of ARA70alpha is consistent with our previous findings that ARA70alpha expression is decreased in prostate cancer cells compared with benign prostate.
  • These results strongly suggest that ARA70alpha functions as a tumor suppressor gene.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 2003 Aug 1;56(3):192-200 [12772188.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1467-74 [12368219.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):7019-29 [12972618.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1032-40 [14871982.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13944-52 [14711828.001]
  • [Cites] Hum Mutat. 2004 Jun;23(6):527-33 [15146455.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33438-46 [15166229.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2979-85 [8187085.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1393-8 [7723794.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5517-21 [8643607.001]
  • [Cites] Prostate. 1998 Apr 1;35(1):63-70 [9537601.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):277-85 [9816170.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):117-28 [9892017.001]
  • [Cites] J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):307-13 [10419007.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4):407-21 [10482183.001]
  • [Cites] Mol Endocrinol. 1999 Oct;13(10):1645-56 [10517667.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7647-54 [15520162.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):342-57 [15648050.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):505-15 [15827323.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5761-8 [15994951.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):251-8 [15982869.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2273-82 [15919721.001]
  • [Cites] Mol Endocrinol. 2005 Dec;19(12):2943-54 [16081517.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1908-16 [16479009.001]
  • [Cites] J Cell Sci. 2006 Jul 1;119(Pt 13):2635-41 [16787944.001]
  • [Cites] Oncogene. 2006 Jun 29;25(28):3905-13 [16636679.001]
  • [Cites] J Cell Biochem. 2006 Oct 1;99(2):373-81 [16598769.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10613-20 [17079486.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):719-33 [17163421.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1432-49 [17416541.001]
  • [Cites] Prostate. 2007 Dec 1;67(16):1801-15 [17935158.001]
  • [Cites] Am J Pathol. 2008 Jan;172(1):225-35 [18156210.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1128-35 [18281488.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5236-41 [18356297.001]
  • [Cites] Biochim Biophys Acta. 2009 Jan;1792(1):14-26 [18992329.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):132-8 [11161850.001]
  • [Cites] Mol Carcinog. 2001 Jan;30(1):1-13 [11255259.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jun;67(3):245-53 [11561770.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10226-35 [11779876.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):207-23 [12085963.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):3001-15 [12089231.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2673-8 [12860943.001]
  • (PMID = 20167864.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK058024
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NCOA4 protein, human; 0 / Nuclear Receptor Coactivators; 0 / Protein Isoforms
  • [Other-IDs] NLM/ PMC2843478
  •  go-up   go-down


64. Beatty JS, Williams HT, Aldridge BA, Hughes MP, Vasudeva VS, Gucwa AL, David GS, Lind DS, Kruse EJ, McLoughlin JM: Incidental PET/CT findings in the cancer patient: how should they be managed? Surgery; 2009 Aug;146(2):274-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 133 patients evaluated further, clinicians identified a second primary malignancy in 41 patients (31%), benign disease in 62 patients (47%), and metastatic disease from their known malignancy in 30 patients (23%).
  • The most common sites for a proven second primary malignancy were: lung (N = 10), breast (N = 7), and colon (N = 5).
  • In our data, approximately half of these findings were benign, a third were consistent with a second primary malignancy or a metastatic focus, and the remainder were never evaluated due to physician and patient decision.
  • Advanced primary tumors are unlikely to be impacted by a second primary tumor suggesting that this subset of patients will not benefit from further investigation.
  • The timing and route of investigation should be dictated by clinical judgment and the status of the primary tumor.
  • [MeSH-major] Incidental Findings. Neoplasms, Second Primary / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Radiopharmaceuticals. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628085.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


65. Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, Mailo D, Palaia R, D'Aiuto G, Botti G, Perrone F, Salomon DS, Normanno N: Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res; 2006 Sep 1;12(17):5158-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of cripto-1 as a novel serologic marker for breast and colon cancer.
  • We evaluated whether CR-1 is present in the plasma of patients with breast and colon cancer, and if it can represent a new biomarker for these malignancies.
  • EXPERIMENTAL DESIGN: We determined CR-1 plasma levels using a sandwich-type ELISA in 21 healthy volunteers, 54 patients with breast cancer, 33 patients with colon carcinoma, and 21 patients with benign breast lesions.
  • A statistically significant increase in the levels of plasma CR-1 was found in patients with colon carcinoma (4.68+/-3.5 ng/mL) and in patients with breast carcinoma (2.97+/-1.48 ng/mL; P<0.001).
  • Although moderate levels of plasma CR-1 were found in women with benign lesions of the breast (1.7+/-0.99 ng/mL), these levels were significantly lower than in patients with breast cancer (P<0.001).
  • Finally, immunohistochemical analysis and real-time reverse transcription-PCR confirmed strong positivity for CR-1 in colon and/or breast tumor tissues.
  • CONCLUSION: This study suggests that plasma CR-1 might represent a novel biomarker for the detection of breast and colon carcinomas.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Colonic Neoplasms / blood. Colonic Neoplasms / diagnosis. Epidermal Growth Factor / blood. Membrane Glycoproteins / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Animals. Enzyme-Linked Immunosorbent Assay / methods. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Intercellular Signaling Peptides and Proteins. Male. Mice. Mice, Transgenic. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951234.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


66. Ishimori T, Patel PV, Wahl RL: Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med; 2005 May;46(5):752-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sites of known or suspected primary tumors included lung (28.6%), colon or rectum (12.4%), head or neck (12.1%), lymph nodes (10.9%), breast (7.6%), gynecologic organs (7.1%), genitourinary organs (4.2%), esophagus (3.6%), skin (melanoma) (3.5%), pancreas (2.5%), bone or soft tissue (2.2%), and other sites (5.4%).
  • Lesions that were newly discovered on PET/CT, had not been previously detected by other modalities, and were atypical in location for metastases on the PET/CT study were interpreted as suggestive of a new primary malignant tumor.
  • These abnormalities were compared with the final diagnosis obtained from the medical records, including pathologic reports.
  • Proven sites were lung (7 lesions), thyroid (6 lesions), colon (4 lesions), breast (2 lesions), esophagus (2 lesions), bile duct (1 lesion), and head and neck other than thyroid (1 lesion).
  • In 8 patients, the PET-positive lesions were considered benign after clinical follow-up of at least 8 mo.
  • In 39 patients, the follow-up record was not yet available and the final diagnosis of the detected lesion has not yet been resolved.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Incidence. Incidental Findings. Male. Middle Aged. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Subtraction Technique / statistics & numerical data. United States / epidemiology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15872346.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Kondi-Pafitis A, Kairi-Vassilatou E, Grapsa D, Kalkounou I, Vassilikostas G, Psichogios I: A large benign vascular neoplasm of the male breast. A case report and review of the literature. Eur J Gynaecol Oncol; 2005;26(4):454-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A large benign vascular neoplasm of the male breast. A case report and review of the literature.
  • Breast hemangiomas are extremely rare neoplasms in the male population.
  • We report a case of a 77-year old man with a breast hemangioma which was detected in physical examination as a small nodule ten years after a chest injury.
  • The final histological diagnosis was hemangioma of the breast, 6 cm in the largest diameter.
  • To our knowledge, this is the largest benign vascular breast neoplasm in a male patient reported up to date.
  • The rarity of the lesion and its differential diagnosis from angiosarcoma are discussed while the problems encountered in the correct diagnosis and classification of this tumor are also presented.
  • The need for extreme caution in the interpretation of the histological characteristics of all palpable vascular tumors of the breast is emphasized.
  • [MeSH-major] Breast Neoplasms, Male / diagnosis. Hemangioma / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Mastectomy, Segmental

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Gynaecol Oncol. 2005;26(6):667; author reply 667-8 [16398236.001]
  • (PMID = 16122203.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 10
  •  go-up   go-down


68. Shukla R, Pooja B, Radhika S, Nijhawan R, Rajwanshi A: Fine-needle aspiration cytology of extramammary neoplasms metastatic to the breast. Diagn Cytopathol; 2005 Apr;32(4):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of extramammary neoplasms metastatic to the breast.
  • Fine-needle aspiration (FNA) biopsy is the first-line investigation in any breast lump and hence cytomorphological recognition of nonmammary metastatic tumors to the breast and their distinction from primary tumors is important.
  • Metastatic breast neoplasms diagnosed over a 6-yr period from 1997 to 2002 were retrieved from the database of the Department of Cytopathology and the clinical, cytopathological, histochemical, and immunohistochemical findings were correlated with the histopathology of the primary tumor.
  • Fifteen cases of metastatic breast neoplasms were encountered constituting 1.47% of all malignant tumors of the breast diagnosed on FNA.
  • There were 14 female patients and one male patient aged 13-80 yr.
  • The preaspiration clinical diagnosis was either a benign breast lump or a malignancy (primary vs. metastatic).
  • The breast lump was the initial presentation in four cases and the cytodiagnosis of a metastatic malignancy lead to the subsequent detection of the primary malignancy.
  • The presence of unusual cytomorphological patterns on breast FNA should alert the cytopathologist to the possibility of a metastatic breast neoplasm, even if not suspected clinically.
  • A detailed history of the patient, clinical correlation, and immunocytochemistry helps in establishing an accurate diagnosis, which avoids unnecessary surgery and ensures appropriate treatment.
  • [MeSH-major] Breast / pathology. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / secondary
  • [MeSH-minor] Adolescent. Adult. Biopsy, Fine-Needle. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15754368.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Kisselbach C, Ristic AD, Pankuweit S, Karatolius K, Maisch B: [Women and pericardial neoplastic manifestations of the heart and pericardium]. Herz; 2005 Aug;30(5):409-15; quiz 429-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the proportions, most women believe that heart disease is a man's disease and that they will die of breast cancer.
  • Data on epidemiology and incidence are rare: there is only an estimated incidence of cardiac neoplasm at necropsy ranging from 0,001% to 0,3%.
  • The majority of the primary tumors are benign.
  • The most common tumor entity is benign cardiac myxoma.
  • They originate mainly from melanomas, leukemias, lymphomas, and cancer, especially of the lung or breast.
  • Indeed in women breast cancer is the most common metastatic tumor associated with pericardial effusion.
  • METHODS: A retrospective study was conducted of all patients with cardiac and pericardial neoplasm exactly diagnosed by endomyocardial or epicardial biopsy and pericardiocentesis, using hospital medical records and a biopsy and pericardiocentesis registry from 2000-2005 with 297 patients.
  • RESULTS: In 76 cases (25.6%) a neoplasm was the reason for a pericardial effusion.
  • 36 women suffered from the breast carcinoma (47%) and 40 males lung cancer (42%) as the firstly metastatic tumor.
  • By contrast, the preventive checkup and aftercare will gain more prognostic importance, especially in case of breast cancer, to earlier recognize a secondary cardiac neoplasm by biopsy and pericardiocentesis with intrapericardial treatment of neoplastic pericarditis.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / secondary. Heart Neoplasms / epidemiology. Heart Neoplasms / secondary. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Registries. Risk Assessment / methods
  • [MeSH-minor] Comorbidity. Female. Germany / epidemiology. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Risk Factors. Sex Distribution. Sex Factors. Women's Health

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132244.001).
  • [ISSN] 0340-9937
  • [Journal-full-title] Herz
  • [ISO-abbreviation] Herz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


70. MacLaughlin BW, Gutsmuths B, Pretner E, Jonas WB, Ives J, Kulawardane DV, Amri H: Effects of homeopathic preparations on human prostate cancer growth in cellular and animal models. Integr Cancer Ther; 2006 Dec;5(4):362-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In homeopathy, Sabal serrulata is commonly prescribed for prostate problems ranging from benign prostatic hyperplasia to prostate cancer.
  • The authors' work assessed the antiproliferative effects of homeopathic preparations of Sabal serrulata, Thuja occidentalis, and Conium maculatum, in vivo, on nude mouse xenografts, and in vitro, on PC-3 and DU-145 human prostate cancer as well as MDA-MB-231 human breast cancer cell lines.
  • Treatment with Sabal serrulata in vitro resulted in a 33% decrease of PC-3 cell proliferation at 72 hours and a 23% reduction of DU-145 cell proliferation at 24 hours (P<.01).
  • No effect was observed on MDA-MB-231 human breast cancer cells.
  • In vivo, prostate tumor xenograft size was significantly reduced in Sabal serrulata-treated mice compared to untreated controls (P=.012).
  • No effect was observed on breast tumor growth.
  • Our study clearly demonstrates a biologic response to homeopathic treatment as manifested by cell proliferation and tumor growth.
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Cell Line, Tumor. Cell Proliferation / drug effects. Conium. Disease Models, Animal. Female. Humans. Male. Mice. Mice, Nude. Serenoa. Thuja. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101766.001).
  • [ISSN] 1534-7354
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / K07 AT001193
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


71. Pruthi RS, Lentz AC, Sand M, Kouba E, Wallen EM: Impact of marital status in patients undergoing radical cystectomy for bladder cancer. World J Urol; 2009 Aug;27(4):573-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Married (vs. unmarried) individuals have improved health status and longer life expectancies in a variety of benign and malignant disease states, including prostate, breast, head/neck, and lung cancers.
  • Married individuals (vs. unmarried) were more often male (84 vs. 62%) and had a higher BMI (28.1 vs. 25.9).
  • These findings may support the evidence (observed in other tumor types and other disease states) that married persons present earlier than unmarried individuals, and this may help explain the improved survival outcomes that have been observed in married patients with bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Marital Status. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Cohort Studies. Creatinine / blood. Female. Follow-Up Studies. Hematocrit. Humans. Length of Stay. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Sep 15;104(6):1188-94 [16078264.001]
  • [Cites] Soc Sci Med. 2003 Dec;57(11):2137-47 [14512244.001]
  • [Cites] Psychooncology. 2008 Sep;17(9):869-76 [18033697.001]
  • [Cites] J Urol. 1996 Nov;156(5):1696-70 [8863573.001]
  • [Cites] Ann Epidemiol. 2000 May;10(4):224-38 [10854957.001]
  • [Cites] Health Psychol. 1988;7(3):269-97 [3289916.001]
  • [Cites] Lancet. 1989 Oct 14;2(8668):888-91 [2571815.001]
  • [Cites] JAMA. 1987 Dec 4;258(21):3125-30 [3669259.001]
  • [Cites] World J Surg. 2003 Mar;27(3):304-8 [12607056.001]
  • [Cites] Am J Epidemiol. 1982 Jul;116(1):123-40 [7102648.001]
  • (PMID = 19219612.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


72. Anyikam A, Nzegwu MA, Ozumba BC, Okoye I, Olusina DB: Benign breast lesions in Eastern Nigeria. Saudi Med J; 2008 Feb;29(2):241-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign breast lesions in Eastern Nigeria.
  • OBJECTIVE: To characterize benign breast diseases in Eastern Nigeria and to highlight the age variations of these lesions as base line data.
  • Seven hundred and twenty-two benign breast specimens were analyzed over 5 years from 1st January 2000 to 31st December 2004, out of 1050 breast samples received.
  • RESULTS: Of 1050 breast specimens received, 722 (68.8%) were benign.
  • Normal breast in the axillary tail region was seen in 32 cases (4.4%), represented as no pathology, with a mean presentation age of 20-46 years.
  • Low grade Phyllodes tumor had 28 cases (3.9%), presenting at an average mean age of 17-32 years.
  • Benign breast lesions peaked at the 20-24 age range and then declined.
  • CONCLUSION: Benign breast lesions occur more frequently than malignant breast lesions with a ratio of 2.3:1 and were presented 20 years earlier than their malignant counterparts.
  • Fibroadenoma was the most common benign lesion followed by fibrocystic disease, similar to the findings in Western Nigeria.
  • In Northern Nigeria, fibrocystic breast disease was more common.
  • [MeSH-major] Breast Diseases / epidemiology. Breast Neoplasms / epidemiology. Fibroadenoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Female. Fibrocystic Breast Disease / epidemiology. Gynecomastia / epidemiology. Humans. Male. Middle Aged. Nigeria / epidemiology. Phyllodes Tumor / epidemiology. Sex Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246234.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


73. Suzuki H, Graziano DF, McKolanis J, Finn OJ: T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res; 2005 Feb 15;11(4):1521-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Cyclin B1-derived peptides were shown by us to be targets of tumor-specific CD8(+) T cells in patients with breast and head and neck cancer.
  • We obtained further evidence of cyclin B1 immunogenicity and its potential to serve as a tumor-specific antigen by analyzing its ability to elicit T cell-dependent humoral immune responses in vivo in patients with different types of tumors.
  • EXPERIMENTAL DESIGN: Recombinant cyclin B1 protein from two different sources was purified and used as antigen in ELISA assays to test sera from patients with breast, pancreatic, colon, and lung cancer for the presence of anti-cyclin B1 antibody.
  • We also analyzed patients with benign lung disease, premalignant disease, and a known history of heavy smoking.
  • Antibodies in patients with breast and colon cancer are primarily of the IgG isotype whereas patients with pancreatic and lung cancer have in addition anti-cyclin B1 IgA.
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / immunology. Breast Neoplasms / metabolism. Colonic Neoplasms / blood. Colonic Neoplasms / immunology. Colonic Neoplasms / metabolism. Cyclin B1. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunohistochemistry. Lung Neoplasms / blood. Lung Neoplasms / immunology. Lung Neoplasms / metabolism. Male. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / immunology. Pancreatic Neoplasms / metabolism. Smoking / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746055.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 090440
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNB1 protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / Immunoglobulin A; 0 / Immunoglobulin G
  •  go-up   go-down


74. Dubb M, Michelow P, Grayson W: Cytologic features of trichoblastoma in fine needle aspiration biopsies. Acta Cytol; 2009 Nov-Dec;53(6):679-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To review the cytologic features of trichoblastoma in order to define criteria that may aid in identification of these tumors at the time of aspiration and allow a definitive diagnosis.
  • STUDY DESIGN: A 58-year-old male presented with a mass lesion on the thigh.
  • On fine needle aspiration, the patient was diagnosed as having a benign skin adnexal tumor.
  • RESULTS: The cytologic features of trichoblastoma resembled a cellular fibroadenoma/phyllodes tumor on aspiration, not previously described in the literature.
  • If the cytomorphology of a skin or subcutaneous aspirate appears to resemble that of a fibroadenoma, the diagnosis of a trichoblastoma should be entertained.
  • Peripheral palisading of nuclei at the edges of the basaloid cell sheets and squamous eddy formation are clues to the diagnosis but may be very focal and could be overlooked.
  • If the tumor occurs in the region of the breast, distinction from a fibroadenoma would be difficult if these additional features were not prominent.
  • CONCLUSION: Knowledge of the cytologic features of trichoblastoma will allow correct management of the patient and prevent misdiagnosis as other benign or malignant tumors.
  • [MeSH-minor] Biopsy, Fine-Needle. Humans. Male. Middle Aged. Thigh / pathology

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014558.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Rekhi B, Jambhekar NA: Morphologic spectrum, immunohistochemical analysis, and clinical features of a series of granular cell tumors of soft tissues: a study from a tertiary referral cancer center. Ann Diagn Pathol; 2010 Jun;14(3):162-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A granular cell tumor (GCT) is relatively uncommon and objectively diagnosed with neural markers on immunohistochemistry (IHC).
  • Herein, we present morphologic spectrum of 12 GCTs of soft tissues and skin, including 10 benign and 2 malignant subtypes with an optimal diagnostic IHC panel.
  • Six cases occurred in soft tissues and skin of extremities, 4 in the breast soft tissues, and 1 case each in the back and preauricular region, respectively.
  • On histopathology, all cases invariably revealed a nonencapsulated infiltrating tumor comprising groups and nests of granular cells with vesicular nuclei.
  • Immunohistochemistry in 10 cases (83.3%) showed diffuse S-100 positivity in all 7 benign and 2 malignant cases: cytoplasmic CD68 positivity (all 10 cases) and membranous vimentin staining (all 4 cases).
  • A GCT is a discrete tumor entity and can be identified from other granular lesions by its proximity to nerves and objective identification with diffuse S-100 positivity, CD68 positivity, and membranous vimentin positivity that form an optimal IHC panel in limited resource settings, irrespective of benign or malignant types.
  • [MeSH-major] Cancer Care Facilities. Granular Cell Tumor / pathology. Referral and Consultation. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers, Tumor / metabolism. Child. Female. Humans. Male. Middle Aged. S100 Proteins / metabolism. Vimentin / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20471560.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


76. Shin SJ, Lesser M, Rosen PP: Hemangiomas and angiosarcomas of the breast: diagnostic utility of cell cycle markers with emphasis on Ki-67. Arch Pathol Lab Med; 2007 Apr;131(4):538-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiomas and angiosarcomas of the breast: diagnostic utility of cell cycle markers with emphasis on Ki-67.
  • CONTEXT: Vascular tumors comprise a minor subgroup of tumors arising in the breast and represent variants of hemangiomas and angiosarcomas.
  • Ki-67 expression has been used as an adjunct to distinguish between benign and malignant lesions exhibiting histologic overlap at various anatomic sites.
  • OBJECTIVE: To investigate the utility of Ki-67 and other cell cycle regulatory proteins (S-phase kinase-associated protein 2 [Skp2], p27, and cyclin D1) in the differential diagnosis of mammary vascular lesions.
  • DESIGN: Thirty-four vascular tumors (21 hemangiomas and 13 angiosarcomas) of the breast were studied.
  • CONCLUSIONS: Ki-67 index can be used as a diagnostic tool to distinguish between benign and malignant vascular lesions of the breast.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms, Male / diagnosis. Hemangioma / diagnosis. Hemangiosarcoma / diagnosis. Ki-67 Antigen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Cycle. Cyclin D1 / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Proliferating Cell Nuclear Antigen / metabolism. S-Phase Kinase-Associated Proteins / metabolism. Sensitivity and Specificity


77. Porcel JM, Salud A, Vives M, Esquerda A, Rodríguez-Panadero F: Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions. Clin Biochem; 2005 Nov;38(11):1031-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate whether pleural levels of the soluble oncoprotein 185 HER-2 (sp185(HER-2)), individually or in combination with CEA and CA 15-3, were useful for the diagnosis of malignant effusions.
  • DESIGN AND METHODS: Levels of CEA, CA 15-3, and sp185(HER-2) were measured in the pleural fluid from 135 malignant and 103 benign effusions.
  • Thresholds of these tumor markers were chosen for a diagnostic specificity of >or=99%.
  • RESULTS: Pleural sp185(HER-2) levels greater than 25 ng/mL were observed in 20% of breast and 10% of lung adenocarcinomas, and predicted a malignant effusion with a sensitivity of 7% and a likelihood ratio of 7.6.
  • Only 1 patient with breast adenocarcinoma among 45 cytology-negative malignant effusions had sp185(HER-2) above the diagnostic cutoff point.
  • [MeSH-major] Biomarkers, Tumor / analysis. Pleural Effusion, Malignant / diagnosis. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Breast Neoplasms / diagnosis. Carcinoembryonic Antigen / analysis. False Negative Reactions. Humans. Likelihood Functions. Lung Neoplasms / diagnosis. Male. Middle Aged. Mucin-1 / analysis. Pleural Effusion / chemistry. Pleural Effusion / diagnosis. Sensitivity and Specificity

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925354.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


78. Chung LW, Baseman A, Assikis V, Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol; 2005 Jan;173(1):10-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
  • PURPOSE: Tumor cell genotype and phenotype have been considered the only determinants supporting cancer growth and metastasis.
  • This review focuses on the published literature that suggests that tumor-microenvironment interaction has a decisive role in controlling local cancer growth, invasion and distant metastasis.
  • As this review shows, genetic alterations in prostate cancer cells alone are not enough to confer metastatic status without a supporting tumor microenvironment.
  • Effective therapeutic targeting requires a deeper understanding of the interplay between tumor and stroma.
  • Approaches co-targeting tumor and stroma already show promise over the conventional targeting of tumor cells alone in preventing prostate cancer progression and eradicating preexisting or newly developed prostate cancers in bone and visceral organs.
  • MATERIALS AND METHODS: A literature survey using the MEDLINE database was performed in basic and clinical publications relevant to tumor-host microenvironment interaction.
  • RESULTS: Tumor associated stroma actively fuel the progression of prostate cancer from localized growth to the invasion of surrounding tissues, and the development of distant bone and visceral organ metastasis.
  • In concert with this progression tumor cells recovered from metastatic sites could represent a subpopulation of preexisting tumor cells or could be a newly acquired variant subsequent to tumor-stromal interaction.
  • This presents a new opportunity for therapeutic targeting for the treatment of benign and malignant growth of the prostate glands.
  • This review summarizes specific research implicating tumor-microenvironment interaction as the molecular basis of cancer progression, providing a rationale for targeting tumor and the tumor associated microenvironment in the management of androgen independent and bone metastatic prostate cancer progression in patients.
  • Further elucidation of the molecular mechanisms underlying tumor-stromal interaction may yield improved medical treatments for prostate cancer growth and metastasis.
  • [MeSH-minor] Bone Neoplasms / physiopathology. Bone Neoplasms / secondary. Breast Neoplasms / physiopathology. Cell Differentiation. Cell Line, Tumor. Cell Transformation, Neoplastic. Disease Progression. Extracellular Matrix / physiology. Fibroblasts / physiology. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Molecular Mimicry. Neoplasm Invasiveness. Signal Transduction / physiology. Vascular Endothelial Growth Factor A / physiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592017.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 098912; United States / NCI NIH HHS / CA / CA 76620
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 73
  •  go-up   go-down


79. Nabarra B, Pontoux C, Godard C, Osborne-Pellegrin M, Ezine S: Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice). Int J Exp Pathol; 2005 Dec;86(6):397-413
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the development of a carcinoma originating from thymic hyperplasia and followed by the formation of a benign tumour composed chiefly of medullary epithelial cells expressing the transgene and of lymphocytes, a pathology very rarely reported in mice.
  • [MeSH-major] Antigens, Polyomavirus Transforming / genetics. Antigens, Viral, Tumor / genetics. Neovascularization, Pathologic. Promoter Regions, Genetic. Pyruvate Kinase / genetics. Thymus Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Immunohistochemistry / methods. Male. Mice. Mice, Inbred CBA. Mice, Transgenic. Microscopy, Immunoelectron. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thymus. 1993 Aug;22(1):13-33 [7508157.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):409-16 [8123467.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2686-98 [8139568.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3979-83 [8171023.001]
  • [Cites] Prog Growth Factor Res. 1994;5(1):89-97 [7515293.001]
  • [Cites] Histopathology. 1994 Jul;25(1):21-9 [7959642.001]
  • [Cites] Int Rev Cytol. 1995;159:113-60 [7537724.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):127-37 [8534862.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] J Pathol. 1995 Nov;177(3):309-15 [8551394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5742-6 [8650163.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Metastasis Rev. 1995 Dec;14(4):263-77 [8821090.001]
  • [Cites] Cancer Lett. 1996 Oct 22;107(2):293-300 [8947527.001]
  • [Cites] Cell. 1997 Jun 13;89(6):981-90 [9200616.001]
  • [Cites] Science. 1997 Jul 4;277(5322):48-50 [9229772.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] Lab Invest. 1990 Jun;62(6):690-6 [1694254.001]
  • [Cites] Lab Invest. 1990 Sep;63(3):298-306 [1697637.001]
  • [Cites] Anticancer Res. 1990 Sep-Oct;10(5A):1335-9 [1700664.001]
  • [Cites] Annu Rev Physiol. 1991;53:217-39 [1710435.001]
  • [Cites] Exp Pathol. 1990;40(4):301-12 [2098275.001]
  • [Cites] Eur J Cancer. 1991;27(6):781-5 [1712608.001]
  • [Cites] Virchows Arch. 1998 Jan;432(1):33-42 [9463585.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Dev Comp Immunol. 2001 Apr;25(3):231-43 [11164888.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):635-42 [12068292.001]
  • [Cites] Immunity. 2002 Jun;16(6):803-14 [12121662.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):2842-5 [12218095.001]
  • [Cites] Mol Aspects Med. 2002 Dec;23(6S):S1-27 [12537983.001]
  • [Cites] Dev Immunol. 2002 Dec;9(4):223-31 [15144019.001]
  • [Cites] Cancer Res. 1975 Oct;35(10):2771-9 [1157049.001]
  • [Cites] Nature. 1979 Mar 15;278(5701):261-3 [218111.001]
  • [Cites] J Mol Biol. 1981 Dec 25;153(4):933-59 [6177862.001]
  • [Cites] Am J Clin Pathol. 1982 Oct;78(4):500-7 [6182789.001]
  • [Cites] Cell. 1982 Sep;30(2):361-72 [6183000.001]
  • [Cites] Differentiation. 1983;23(3):256-69 [6189757.001]
  • [Cites] Pathol Res Pract. 1982;175(2-3):256-65 [6190148.001]
  • [Cites] Am J Pathol. 1984 Jan;114(1):121-30 [6197886.001]
  • [Cites] J Pathol. 1983 Nov;141(3):385-413 [6198502.001]
  • [Cites] Lab Invest. 1984 Jan;50(1):36-41 [6198559.001]
  • [Cites] Cell. 1984 Jun;37(2):367-79 [6327063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11822-7 [9751749.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1474-81 [9850173.001]
  • [Cites] Semin Diagn Pathol. 1999 Feb;16(1):2-17 [10355650.001]
  • [Cites] Pathology. 1998 May;30(2):111-22 [9643488.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7533-7 [8356051.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5797-804 [6209004.001]
  • [Cites] Lab Invest. 1985 Jan;52(1):31-8 [2578201.001]
  • [Cites] Lab Invest. 1985 Mar;52(3):243-56 [2579289.001]
  • [Cites] Mol Cell Biol. 1985 Apr;5(4):642-8 [2985963.001]
  • [Cites] J Natl Cancer Inst. 1985 Aug;75(2):369-79 [3860689.001]
  • [Cites] Nature. 1985 Aug 1-7;316(6027):457-60 [2991771.001]
  • [Cites] Lab Invest. 1986 Nov;55(5):521-30 [2430138.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] J Virol. 1987 Jun;61(6):2029-32 [3033329.001]
  • [Cites] Thymus. 1987;9(2):95-121 [3296336.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3178-84 [3118193.001]
  • [Cites] EMBO J. 1987 Sep;6(9):2699-704 [2824189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 May;85(9):3135-9 [2452444.001]
  • [Cites] J Comp Pathol. 1988 Aug;99(2):187-203 [2846660.001]
  • [Cites] Toxicol Pathol. 1988;16(3):321-6 [3194653.001]
  • [Cites] Cell Tissue Res. 1988 Oct;254(1):225-31 [2461804.001]
  • [Cites] Oncogene Res. 1988;3(1):87-97 [3060799.001]
  • [Cites] Annu Rev Genet. 1988;22:479-519 [3071256.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cell. 1989 Sep 8;58(5):803-5 [2673531.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6108-17 [2551499.001]
  • [Cites] Am J Pathol. 1989 Oct;135(4):679-95 [2552813.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Am J Surg Pathol. 1990 Feb;14(2):151-66 [1689123.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]
  • [Cites] Semin Immunol. 1990 Jan;2(1):13-24 [1717051.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1161-7 [1957168.001]
  • [Cites] J Clin Invest. 1992 Jan;89(1):244-53 [1729274.001]
  • [Cites] Mol Biol Cell. 1992 Feb;3(2):211-20 [1550962.001]
  • [Cites] Development. 1992 Feb;114(2):521-32 [1592003.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Oncogene. 1992 Nov;7(11):2175-87 [1279498.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):99-105 [7677978.001]
  • [Cites] Cancer Treat Res. 1992;63:359-71 [1284027.001]
  • [Cites] Cell. 1993 Mar 26;72(6):835-46 [7681362.001]
  • [Cites] FASEB J. 1993 Jul;7(10):866-71 [8344486.001]
  • [Cites] Toxicol Pathol. 1993;21(2):206-18 [8210943.001]
  • [Cites] Immunol Today. 1993 Sep;14(9):445-59 [8216723.001]
  • [Cites] Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24 [8281615.001]
  • (PMID = 16309545.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Antigens, Viral, Tumor; 0 / Biomarkers, Tumor; EC 2.7.1.40 / Pyruvate Kinase
  • [Other-IDs] NLM/ PMC2517450
  •  go-up   go-down


80. Vourtsi A, Zervoudis S, Pafiti A, Athanasiadis S: Male breast hemangioma--a rare entity: a case report and review of the literature. Breast J; 2006 May-Jun;12(3):260-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast hemangioma--a rare entity: a case report and review of the literature.
  • We report the case of a 77-year-old man with a very rare breast tumor: hemangioma.
  • The histology confirmed the diagnosis of benign hemangioma.
  • There is very little literature on this type of tumor in men.
  • Generally hemangiomas are large and ultrasound and magnetic resonance imaging (MRI) are useful for the diagnosis.
  • The important differential diagnosis with angiosarcoma is based on specific histologic patterns.
  • [MeSH-major] Breast Neoplasms, Male / diagnosis. Hemangioma / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Mastectomy, Segmental


81. Niedźwiecki S, Stepień T, Kuzdak K, Stepień H, Krupiński R, Seehofer D, Rayes N, Ulrich F: Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbecks Arch Surg; 2008 May;393(3):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We measured preoperative IL-1ra serum levels of 52 consecutive patients with thyroid cancer, 15 with benign adenoma and 27 healthy volunteers.
  • The final histological diagnosis revealed 21 patients with papillary and 8 patients with follicular carcinoma (FTC), while 12 cases of medullary and 11 cases of anaplastic carcinoma (ATC) were observed.
  • [MeSH-major] Biomarkers, Tumor / blood. Interleukin 1 Receptor Antagonist Protein / blood. Thyroid Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / surgery. Adenocarcinoma, Papillary / blood. Adenocarcinoma, Papillary / surgery. Adenoma / blood. Adenoma / surgery. Adult. Aged. Carcinoma / blood. Carcinoma / surgery. Carcinoma, Medullary / blood. Carcinoma, Medullary / surgery. Female. Humans. Male. Middle Aged. Reference Values. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Langenbecks Arch Surg. 2009 Mar;394(2):401-2; author reply 403 [18825404.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11008-13 [8855299.001]
  • [Cites] Lancet. 1987 Nov 28;2(8570):1240-2 [2890857.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):197-202 [16319982.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1501-4 [14504049.001]
  • [Cites] Am J Med. 1990 Nov;89(5):621-9 [2239982.001]
  • [Cites] J Immunol. 1991 Dec 15;147(12):4218-23 [1836481.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):794-803 [8362978.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Dec;104(12):1407-8 [9422021.001]
  • [Cites] J Am Coll Surg. 1994 Feb;178(2):132-8 [8173722.001]
  • [Cites] Scand J Gastroenterol. 1999 Nov;34(11):1139-43 [10582766.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):1066-76 [9185713.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):269-75 [1531398.001]
  • [Cites] Cancer Lett. 1999 Aug 3;142(2):179-84 [10463774.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Apr;292(4):R1667-74 [17138728.001]
  • [Cites] J Int Med Res. 2007 May-Jun;35(3):395-405 [17593869.001]
  • [Cites] J Biol Chem. 1991 Jun 5;266(16):10331-6 [1828071.001]
  • [Cites] Blood. 1992 May 1;79(9):2196-200 [1533321.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1627-52 [1826616.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1738-43 [7908231.001]
  • [Cites] Arthritis Rheum. 1995 Aug;38(8):1055-9 [7639800.001]
  • [Cites] J Exp Med. 1999 Jun 21;189(12):1863-74 [10377182.001]
  • [Cites] Annu Rev Immunol. 1998;16:27-55 [9597123.001]
  • [Cites] J Clin Invest. 1997 Jun 15;99(12):2930-40 [9185517.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Apr;31(4):719-24 [17317198.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):161-4 [1832651.001]
  • [Cites] Scand J Immunol. 1998 Mar;47(3):195-8 [9519856.001]
  • [Cites] J Soc Gynecol Investig. 2002 Nov-Dec;9(6):386-90 [12445604.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2339-45 [15800325.001]
  • [Cites] J Immunol. 1993 May 1;150(9):4008-18 [8473746.001]
  • [Cites] Clin Infect Dis. 2002 Jan 15;34(2):204-9 [11740709.001]
  • [Cites] Eur Cytokine Netw. 1994 Nov-Dec;5(6):517-31 [7727685.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):493-7 [16106254.001]
  • [Cites] Prog Growth Factor Res. 1990;2(4):193-205 [2151936.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3282-8 [8605344.001]
  • [Cites] Clin Exp Immunol. 1995 Feb;99(2):303-10 [7851026.001]
  • [Cites] Gastric Cancer. 2006;9(4):284-90 [17235630.001]
  • [Cites] Int J Oncol. 1999 Dec;15(6):1251-4 [10568836.001]
  • [Cites] Lancet. 1992 Oct 17;340(8825):968 [1357359.001]
  • [Cites] Pharmacol Res. 2007 Feb;55(2):131-8 [17174563.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2007 Mar;27(3):387-9 [17426001.001]
  • [Cites] Arthritis Rheum. 1994 Dec;37(12):1744-51 [7986220.001]
  • (PMID = 18064485.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IL1RN protein, human; 0 / Interleukin 1 Receptor Antagonist Protein
  •  go-up   go-down


82. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS, Geradts J: Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum Pathol; 2007 Nov;38(11):1628-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.
  • The purpose of this study was to understand the characteristics of prostate-derived Ets factor (PDEF) protein expression in breast and prostate cancer progression.
  • A polyclonal antibody specific to PDEF was raised and reacted with tissue microarrays consisting of benign breast, in situ ductal, invasive ductal, and invasive lobular breast carcinomas.
  • The antibody was also reacted with tissue microarrays, including benign prostate, prostate intraepithelial neoplasias (PINs), and prostate carcinomas.
  • Increased expression of PDEF was identified in 18%, 50%, 46%, and 51% of benign breast tissues, intraductal, invasive ductal, and invasive lobular carcinomas, respectively.
  • Importantly, in matched samples of benign breast vs tumor, 90% showed higher expression of PDEF in the tumor tissue.
  • Moreover, in invasive breast carcinomas, increased PDEF expression tended to correlate with Her2/neu overexpression.
  • Increased expression of PDEF was also found in 27%, 33%, and 40% of benign prostate tissues, PIN samples, and prostate adenocarcinomas, respectively.
  • Again, in matching samples of cancer vs benign and cancer vs PIN, 68% and 70%, respectively, showed increased expression in the malignant tissue.
  • In addition, R1881 treatment induced PDEF expression in the LNCaP prostate tumor cell line, suggesting regulation of PDEF by androgens in vivo.
  • Together, these results for the first time show frequent increased expression of PDEF protein in breast and prostate tumors and support a role for PDEF in breast and prostate cancer progression.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Steroids. 2007 Jan;72(1):7-25 [17169390.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):176-84 [16858179.001]
  • [Cites] Cancer Biol Ther. 2007 Jan;6(1):76-82 [17172821.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):19-30 [16897429.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1216-25 [10625666.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1348-52 [10728697.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):688-96 [11041059.001]
  • [Cites] Crit Rev Oncog. 2000;11(3-4):227-53 [11358268.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2731-8 [11555586.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Nov;2(11):827-37 [11715049.001]
  • [Cites] Bioessays. 2002 Apr;24(4):362-70 [11948622.001]
  • [Cites] Climacteric. 2002 Mar;5(1):15-25 [11974555.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Apr;17(2):137-49 [12030108.001]
  • [Cites] Curr Cancer Drug Targets. 2001 May;1(1):49-57 [12188891.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4626-31 [12907642.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11281-92 [14662758.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):459-76 [15369448.001]
  • [Cites] BMJ. 1997 Jun 28;314(7098):1843-4 [9224112.001]
  • [Cites] Breast Cancer Res. 2004;6(6):229-39 [15535852.001]
  • [Cites] Annu Rev Med. 2005;56:117-37 [15660505.001]
  • [Cites] Curr Opin Urol. 2005 May;15(3):181-6 [15815195.001]
  • [Cites] Curr Opin Urol. 2005 May;15(3):187-95 [15815196.001]
  • [Cites] Curr Opin Oncol. 2005 May;17(3):257-60 [15818171.001]
  • [Cites] J Endocrinol Invest. 2005;28(3 Suppl):8-13 [16044581.001]
  • [Cites] Curr Pharm Des. 2005;11(22):2873-87 [16101443.001]
  • [Cites] Am J Pharmacogenomics. 2005;5(5):327-38 [16196502.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11572-80 [16357167.001]
  • [Cites] Curr Gene Ther. 2006 Feb;6(1):17-33 [16475943.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):1-7 [16790693.001]
  • (PMID = 17521701.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / CA 86164; United States / NCI NIH HHS / CA / CA086164-03; United States / NCI NIH HHS / CA / R41 CA086164-03; United States / NCI NIH HHS / CA / P30 CA 16056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-ets; 0 / SPDEF protein, human; 2C323EGI97 / Metribolone
  • [Other-IDs] NLM/ NIHMS33974; NLM/ PMC2121591
  •  go-up   go-down


83. Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, Lavin MF, Gardiner RA: Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer; 2008 Aug 5;99(3):491-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Claudin-4, coding for an integral membrane cell-junction protein, was the most significantly (P<0.00001) upregulated marker in both primary and metastatic tumour specimens compared with benign prostatic hyperplasia at both RNA and protein levels.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Membrane Proteins / metabolism. Prostatic Neoplasms / pathology. Prostatic Neoplasms / secondary
  • [MeSH-minor] Base Sequence. Blotting, Western. Cell Line, Tumor. Claudin-4. DNA Primers. Humans. Immunohistochemistry. Male. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate Suppl. 2000;9:4-14 [11056496.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):564-9 [17306334.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Histol Histopathol. 2001 Oct;16(4):1183-95 [11642738.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;963:169-84 [12095942.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):228-37 [12115574.001]
  • [Cites] Urology. 2003 Apr;61(4):736-41 [12670557.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Urol. 2004 Jan;171(1):187-91 [14665873.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6357-62 [14695135.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):903-14 [14982844.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):271-2 [15245824.001]
  • [Cites] Tumori. 2004 Nov-Dec;90(6):535-46 [15762353.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):950-6 [15609297.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4334-42 [15899825.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] J Urol. 2000 Aug;164(2):411-5 [10893598.001]
  • [Cites] Cell. 2000 Oct 13;103(2):295-309 [11057902.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):328-34 [15327539.001]
  • [Cites] Infect Immun. 1971 Aug;4(2):89-96 [4343403.001]
  • [Cites] Adv Cancer Res. 1976;23:23-89 [179291.001]
  • [Cites] Biochem Biophys Res Commun. 1979 Nov 28;91(2):629-36 [229852.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1732-6 [7523720.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):218-22 [8548767.001]
  • [Cites] J Cell Biol. 1997 Mar 24;136(6):1239-47 [9087440.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3629-34 [9288760.001]
  • [Cites] J Biol Chem. 1997 Oct 17;272(42):26652-8 [9334247.001]
  • [Cites] Prostate. 1998 Sep 15;37(1):19-29 [9721065.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):511-6 [9892664.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1017-24 [10379964.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3192-8 [10397265.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):193-9 [15643498.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7378-85 [16103090.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):708-15 [16203278.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4549-52 [16651402.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):231-6 [16678055.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21433-44 [16714763.001]
  • [Cites] Carcinogenesis. 2007 Feb;28(2):246-58 [16829686.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):1-2 [11144889.001]
  • (PMID = 18648369.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN4 protein, human; 0 / Claudin-4; 0 / DNA Primers; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2527792
  •  go-up   go-down


84. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM: Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol; 2007 Mar;20(3):375-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant expression of human leukocyte antigen G (HLA-G) has been proposed to be involved in tumor escape mechanisms.
  • It has been also proposed that detection of HLA-G might service as a potential biomarker for diagnosis or prediction of the clinical outcomes in ovarian and breast cancers, carcinoma of the lung and endometrial cancer.
  • In this prospectively study, HLA-G protein expression was observed in 64.6% (130/201) of the primary site colorectal carcinomas, but not in the normal colorectal tissues or benign adenomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis
  • [MeSH-minor] Female. HLA-G Antigens. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277760.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


85. Hu Y, Zhang S, Yu J, Liu J, Zheng S: SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast; 2005 Aug;14(4):250-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer.
  • Breast cancer has never had any good serum tumor markers.
  • SELDI-TOF-MS ProteinChip was used to detect the serum protein patterns of 49 breast cancer patients, 51 patients with benign breast diseases, and 33 healthy women.
  • The abilities of these models to diagnose stage I breast cancer were not worse than for stages II-IV (P>0.05).
  • Four candidate biomarkers of breast cancer were found.
  • The high sensitivity and specificity achieved by this method show great potential for the early detection of breast cancer and facilitation of discovering new and improved biomarkers.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Computational Biology. Proteomics / methods
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Mass Spectrometry / methods. Middle Aged. Protein Array Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085230.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


86. Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ: Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer; 2008 May 6;98(9):1562-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MUC1 mRNA expression was significantly higher in mesothelioma samples than in benign mesothelial cells.
  • CA15.3 (soluble MUC1) levels were significantly higher in the serum of mesothelioma patients than in healthy controls but were not significantly different to levels in patients with benign asbestos-related disease.
  • CA15-3 in effusions could differentiate malignant from benign effusions but were not specific for mesothelioma.
  • Thus, as in other cancers, alterations in MUC1 biology occur in mesothelioma and these results suggest that specific MUC1 characteristics may be useful for mesothelioma diagnosis and should also be investigated as a potential therapeutic target.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Mucin-1 / metabolism. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Alternative Splicing. Female. Gene Expression Regulation, Neoplastic. Glycosylation. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Polymerase Chain Reaction. RNA, Messenger / metabolism. Sensitivity and Specificity. Up-Regulation

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1059-65 [10576665.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5129-35 [16951230.001]
  • [Cites] Cytopathology. 2000 Jun;11(3):139-51 [10877273.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3102-8 [11049990.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):9-16 [11162861.001]
  • [Cites] Curr Opin Mol Ther. 2001 Feb;3(1):102-5 [11249725.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):166-71 [12115565.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8 [12620150.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):289-94 [12781427.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Histopathology. 2004 Feb;44(2):147-55 [14764058.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(2):189-231 [15270554.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1131-5 [15387710.001]
  • [Cites] Ann Intern Med. 1972 Oct;77(4):507-13 [4642731.001]
  • [Cites] Br J Cancer. 1985 Sep;52(3):347-54 [3899155.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):755-61 [7679050.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5847s-5851s [7493358.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:88-99 [9422093.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:111-7 [9422095.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Diagn Cytopathol. 2005 Mar;32(3):156-9 [15690334.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):63-7 [15864588.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77 [16467101.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5910-8 [16740731.001]
  • [Cites] J Urol. 2006 Jul;176(1):91-5 [16753376.001]
  • [Cites] Tumour Biol. 2000 Jul-Aug;21(4):197-210 [10867613.001]
  • (PMID = 18454162.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2391110
  •  go-up   go-down


87. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ: Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res; 2005 Aug 01;65(15):6640-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
  • Putative prostate stem cells and prostate tumor stem cells in benign and malignant human prostate tissue, in primary human prostate xenografts, and in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of prostate cancer, are defined by expression of breast cancer resistance protein (BCRP), a marker of pluripotent hematopoietic, muscle, and neural stem cells, and by an absence of androgen receptor (AR) protein.
  • In both benign and malignant human prostate tissue, the rare epithelial cells that express BCRP and lack AR protein are localized in the basal cell compartment, survive androgen deprivation, and maintain proliferative potential in the hypoxic, androgen-deprived prostate.
  • Putative prostate tumor stem cells that express BCRP but not AR protein in TRAMP are the source of a BCRP-negative and AR-negative, Foxa2- and SV40Tag-expressing, transit amplifying compartment that progresses to the poorly differentiated carcinomas that arise rapidly after castration.
  • Therefore, BCRP expression isolates prostate stem/tumor stem cells from the prostate tissue microenvironment through constitutive efflux of androgen, protecting the putative tumor stem cells from androgen deprivation, hypoxia, or adjuvant chemotherapy, and providing the nidus for recurrent prostate cancer.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. Androgens / metabolism. Neoplasm Proteins / biosynthesis. Neoplastic Stem Cells / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Animals. Cell Line. Cell Nucleus / metabolism. Humans. Indoles / pharmacology. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Novobiocin / pharmacology. Prostate / metabolism. Protein Processing, Post-Translational. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Rats. Receptors, Androgen / biosynthesis. Receptors, Androgen / deficiency. Receptors, Androgen / genetics. Receptors, Androgen / metabolism. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVOBIOCIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061644.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA84296; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739; United States / NCI NIH HHS / CA / CA64851; United States / NIEHS NIH HHS / ES / ES07017; United States / NCI NIH HHS / CA / CA64865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Androgens; 0 / Indoles; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Androgen; 17EC19951N / Novobiocin; CW5S8OP3VO / tryptoquivaline
  •  go-up   go-down


88. Jung EM, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F: Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study. World J Gastroenterol; 2007 Dec 21;13(47):6356-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred patients with histologically confirmed malignant or benign hepatic tumor (maximum size 5 cm) were analyzed.
  • The cut-off of the gray value differences between tumor and normal liver tissue was established using Receiver Operating Characteristic (ROC) analysis 64-line multi-slice computed tomography served as reference method in all cases.
  • RESULTS: One hundred patients with 59 malignant (43 colon, 5 breast, 2 endocrine metastases, 7 hepatocellular carcinomas and 2 kidney cancers) and 41 benign (15 hemangiomas, 7 focal nodular hyperplasias, 5 complicated cysts, 2 abscesses and 12 circumscribed fatty changes) tumors were included.
  • The late venous phase proved to be the most sensitive for classification of the tumor type.
  • Of the 41 benign tumors, 37 were classified as true negative and 4 as false negative, which corresponds to a specificity of 90.2%.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Germany. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Angiography. Male. Middle Aged. Observer Variation. Predictive Value of Tests. Prospective Studies. ROC Curve. Reproducibility of Results. Sensitivity and Specificity. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081224.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  • [Other-IDs] NLM/ PMC4205454
  •  go-up   go-down


89. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • Salivary gland-type neoplasms of the breast are uncommon and comprise numerous entities analogous to that more commonly seen in salivary glands.
  • The clinicopathologic spectrum ranges from benign to malignant but there are important differences as compared with those of their salivary counterpart.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • It is also important to appreciate that in contrast to "triple negative" conventional breast carcinomas with aggressive course, most salivary-type malignant breast neoplasms behave in a low-grade manner.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adenomyoepithelioma / metabolism. Adenomyoepithelioma / pathology. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Male. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


90. Ribeiro-Silva A, Mendes CF, Costa IS, de Moura HB, Tiezzi DG, Andrade JM: Metastases to the breast from extramammary malignancies: a clinicopathologic study of 12 cases. Pol J Pathol; 2006;57(3):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases to the breast from extramammary malignancies: a clinicopathologic study of 12 cases.
  • Along with a brief review of the literature, we report the clinicopathologic features of 12 cases of extramammary malignancies metastatic to the breast.
  • Histological diagnoses of the primary tumor were as follows: non-Hodgkin diffuse large B-cell lymphoma (3 patients), acute mycloid leukemia (3 patients), serous papillary adenocarcinoma, well-differentiated adenocarcinoma, squamous cell carcinoma, undifferentiated neoplasm, mesothelioma, and melanoma.
  • The interval between diagnosis of primary cancer and the appearance of breast metastasis ranged from 0 to 108 months (mean: 17, median: 1).
  • Survival after the detection of the breast metastases ranged from 0.2 to 144 months (mean: 23, median: 9.5).
  • In conclusion, metastasis can mimic either benign disease or primary malignancy and is often an unexpected diagnosis in a patient presenting with a breast mass.
  • Thus, an accurate diagnosis is important to avoid unnecessary mutilating surgery.
  • [MeSH-major] Breast Neoplasms / secondary. Neoplasm Metastasis
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / secondary. Child. Female. Humans. Male. Mammography. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219743.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


91. Makkat S, Luypaert R, Sourbron S, Stadnik T, De Mey J: Assessment of tumor blood flow in breast tumors with T1-dynamic contrast-enhanced MR imaging: impact of dose reduction and the use of a prebolus technique on diagnostic efficacy. J Magn Reson Imaging; 2010 Mar;31(3):556-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of tumor blood flow in breast tumors with T1-dynamic contrast-enhanced MR imaging: impact of dose reduction and the use of a prebolus technique on diagnostic efficacy.
  • PURPOSE: To prospectively evaluate whether dose reduction and the application of a prebolus technique can effectively alleviate signal saturation effects in T1 dynamic contrast enhanced (T1-DCE) magnetic resonance imaging (MRI) data in breast tumors and lead to increased diagnostic efficacy of the regional tumor blood flow (TBF) values obtained with deconvolution of T1-DCE MRI data.
  • MATERIALS AND METHODS: After obtaining informed consent, 23 women (32-80 years) with histologically proven breast tumors underwent MR mammography that included a whole-breast T1 DCE sequence.
  • In the slice where the tumor enhanced maximally, a prebolus protocol was applied.
  • The relative enhancement time course from the tumor region of interest was deconvolved with the reconstructed AIF to generate the impulse response function, the maximum of which yielded the TBF.
  • RESULTS: Reducing the contrast dose by a factor of 2 led to an increase in diagnostic contrast for the TBF values of malignant and benign tumors by a factor of slightly more than 2.
  • CONCLUSION: Using a prebolus approach provides an estimate of the unsaturated AIF, while reduction of the high-dose bolus minimizes possible saturation effects in the tumor time course.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / physiopathology. Magnetic Resonance Imaging / methods. Neovascularization, Pathologic / diagnosis. Neovascularization, Pathologic / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Flow Velocity. Humans. Male. Middle Aged. Radiation Dosage. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20187197.001).
  • [ISSN] 1522-2586
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Ohtsuka H: Chondrolipoma of the popliteal fossa and Japanese reports. J Dermatol; 2006 Mar;33(3):202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients were male and five were female.
  • Two lesions each arose on the tongue, upper back and popliteal fossa, and one each on the buccal submucosa, shoulder, breast, lateral chest and sole.
  • The presented tumor was an early one because of the shortest duration and the smallest size in Japan.
  • Recent criteria for a benign mesenchymoma including a chondrolipoma were also described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620227.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 18
  •  go-up   go-down


93. Mainiero MB, Cinelli CM, Koelliker SL, Graves TA, Chung MA: Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance. AJR Am J Roentgenol; 2010 Nov;195(5):1261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance.
  • OBJECTIVE: The objective of our study was to evaluate the utility of ultrasound-guided fine-needle aspiration (FNA) of the axillary lymph nodes in breast cancer patients depending on the size of the primary tumor and the appearance of the lymph nodes.
  • SUBJECTS AND METHODS: Data were collected about tumor size, lymph node appearance, and the results of ultrasound-guided FNA and axillary surgery of 224 patients with breast cancer undergoing 226 ultrasound-guided FNA.
  • Lymph nodes were classified as benign if the cortex was even and measured < 3 mm, indeterminate if the cortex was even but measured ≥ 3 mm or measured < 3 mm but was focally thickened, and suspicious if the cortex was focally thickened and measured ≥ 3 mm or the fatty hilum was absent.
  • The results of ultrasound-guided FNAs were analyzed by the sonographic appearance of the axillary lymph nodes and by the size of the primary tumor.
  • [MeSH-major] Axilla / pathology. Biopsy, Fine-Needle / methods. Breast Neoplasms / pathology. Lymphatic Metastasis / pathology. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / surgery. Breast Neoplasms, Male / ultrasonography. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Prospective Studies. Sensitivity and Specificity. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJR Am J Roentgenol. 2011 Jul;197(1):W194; author reply W195 [21700988.001]
  • (PMID = 20966338.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Li BJ, Huang XP, Wei WD, Wang JY, Su XD, Zhang X, Hong WS, Tang J, Zhang LJ, Long H, Yang MT, Rong TH: [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. Ai Zheng; 2005 Jun;24(6):735-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer].
  • BACKGROUND & OBJECTIVE: Breast cancer may undergo metastasis in early phase.
  • Distant metastasis, especially bone metastasis, may influence prognosis of breast cancer patients.
  • This study was designed to evaluate expression and clinical significance of cytokeratin 19 (CK19) in bone marrow of patients with breast cancer.
  • METHODS: Expression of CK19 mRNA in bone marrows of 65 breast cancer patients, 15 benign breast disease patients, and 8 healthy volunteers was detected by reverse transcription-polymerase chain reaction (RT-PCR).
  • Correlation of CK19 mRNA expression to clinicopathologic features of the 65 breast cancer patients was analyzed.
  • RESULTS: Positive rate of CK19 mRNA was 33.8% in the 65 breast cancer patients, and 0 in both benign breast disease patients and healthy volunteers.
  • Expression of CK19 mRNA was positively correlated with tumor size and clinical stage (P < 0.05), but was not related to age and lymph node status (P > 0.05).
  • CONCLUSIONS: CK19 mRNA may be used as a molecular marker to detect bone marrow micrometastasis in patients with breast cancer.
  • The detection may help to select proper therapy and predict prognosis of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Keratin-19 / biosynthesis
  • [MeSH-minor] Adult. Aged. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoembryonic Antigen / blood. Female. Fibroadenoma / blood. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946491.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


95. Kupka S, Haack B, Zdichavsky M, Mlinar T, Kienzle C, Bock T, Kandolf R, Kroeber SM, Königsrainer A: Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel. J Cancer Res Clin Oncol; 2008 Apr;134(4):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Pheochromocytoma (PCC) is a usually benign tumor originated in the majority of patients from the adrenal medulla.
  • Among the 23 patients with endocrine tumors, only three (one pancreatic endocrine tumor, one duodenal neuro-endocrine tumor, one hepatic metastasis of a primary tumor with unknown origin) demonstrated MSI.
  • [MeSH-minor] Adult. Aged. Colorectal Neoplasms / genetics. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Teratog Carcinog Mutagen. 2003;Suppl 1:255-65 [12616616.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):241-9 [15944796.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):353-60 [11433399.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3444-9 [11705861.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1564-7 [15619218.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):285-92 [11196176.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):93-8 [17143284.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1114-5 [17021141.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):895-903 [9536095.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] In Vivo. 2005 Mar-Apr;19(2):359-65 [15796198.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):322-9 [11979373.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2536-40 [12171881.001]
  • [Cites] Int J Colorectal Dis. 2006 Oct;21(7):625-31 [16557375.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):10-1 [17192781.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):300-3 [9521327.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):128-35 [15066320.001]
  • [Cites] World J Surg. 2006 Jul;30(7):1240-6 [16715450.001]
  • [Cites] Exp Mol Med. 2004 Apr 30;36(2):122-9 [15150440.001]
  • [Cites] Breast Cancer Res Treat. 2000 Mar;60(2):135-42 [10845276.001]
  • [Cites] Surgery. 2003 Dec;134(6):902-8; discussion 909 [14668721.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Cancer Treat Rev. 2006 Dec;32(8):607-18 [17055172.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):145-52 [16724208.001]
  • (PMID = 17828419.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Xu F, Liu B, Chen XY, Zhou EX, Fan DF, Ma Y, Tang ZH: [Diagnosis and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Feb;11(2):120-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases].
  • OBJECTIVE: To explore the clinical characteristics, diagnosis and therapy of thyroid carcinoma in children.
  • RESULTS: A hard thyroid mass was observed in 10 out of 12 children with thyroid carcinoma, but only one out of 15 children with benign thyroid tumor (<0.05).
  • The rate of cervical lymph node metastasis in children with thyroid carcinoma was significantly higher than that in children with benign thyroid tumor (<0.05).
  • A combination of ultrasonography and CT is helpful to the diagnosis of childhood thyroid carcinoma.
  • [MeSH-major] Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Female. Follow-Up Studies. Humans. Iodine Radioisotopes / therapeutic use. Male. Postoperative Complications / etiology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222949.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


97. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK: 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope; 2005 Jun;115(6):1074-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the prevalence of incidental thyroid F-fluorodeoxyglucose (FDG) uptake in positron emission tomogram (PET) scan for evaluation in cancer patients and the role of standard uptake value (SUV) measurement in differentiation of thyroid malignancy from benign disease.
  • Cytologic diagnosis was available in 32 of 45 focal thyroid FDG uptakes.
  • In 16 (50%) patients, the tumor was found to be malignant; 14 were papillary thyroid carcinoma (surgically confirmed in 7 cases), 2 were metastatic tumor from breast and esophagus.
  • Sixteen were cytologically diagnosed as follicular cell lesions: follicular neoplasm (n = 2), nodular hyperplasia (n = 7), indeterminate follicular lesion (n = 7).
  • There was no significant difference in maximum SUV between benign and malignant nodules.
  • From 45 patients with diffuse thyroid FDG uptake, presumptive diagnosis of chronic thyroiditis was possible in 34 patients by clinical and laboratory findings.
  • CONCLUSION: Our data suggest that a cytologic diagnosis of focal thyroid FDG-PET incidentaloma regardless of SUV is mandatory considering the very high prevalence of thyroid malignancy.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radionuclide imaging. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Thyroid Nodule / radionuclide imaging. Thyroiditis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933524.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. Mullaney PJ, Becker E, Graham B, Ghazarian D, Riddell RH, Salonen DC: Benign hidradenoma: magnetic resonance and ultrasound features of two cases. Skeletal Radiol; 2007 Dec;36(12):1185-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign hidradenoma: magnetic resonance and ultrasound features of two cases.
  • Tumors of sweat gland origin are rare in the hand but should be considered in the differential diagnosis when certain imaging features are present.
  • The imaging literature of this tumor is reviewed, and its significance is discussed with respect to the current understanding of its malignant potential.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Fingers. Magnetic Resonance Imaging. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Humans. Male. Middle Aged. Ultrasonography

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1968 Jun;97(6):651-61 [4297448.001]
  • [Cites] AJR Am J Roentgenol. 2002 Oct;179(4):1079-80 [12239078.001]
  • [Cites] Radiat Med. 2004 Nov-Dec;22(6):426-8 [15648460.001]
  • [Cites] J Surg Oncol. 1990 Feb;43(2):131-3 [2154644.001]
  • [Cites] Breast J. 2007 Jan-Feb;13(1):91-3 [17214802.001]
  • [Cites] J Am Podiatr Med Assoc. 1998 Oct;88(10):510-3 [9791957.001]
  • [Cites] Skeletal Radiol. 1999 Feb;28(2):104-6 [10197457.001]
  • [Cites] Clin Radiol. 2004 Dec;59(12 ):1142-4 [15556599.001]
  • [Cites] Am Surg. 1999 Mar;65(3):236-40 [10075300.001]
  • [Cites] J Comput Assist Tomogr. 2000 Mar-Apr;24(2):293-5 [10752896.001]
  • (PMID = 17624528.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •